|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions decreases expression |
ISO |
caffeic acid phenethyl ester promotes the reaction [Nitrogen Mustard Compounds results in decreased expression of AHR protein] |
CTD |
PMID:17204746 |
|
NCBI chr 6:54,963,990...55,001,806
Ensembl chr 6:54,963,990...55,001,464
|
|
G |
Alb |
albumin |
increases alkylation |
ISO |
Nitrogen Mustard Compounds results in increased alkylation of ALB protein |
CTD |
PMID:18269793 |
|
NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
|
|
G |
Brca1 |
BRCA1, DNA repair associated |
decreases expression multiple interactions |
ISO |
Nitrogen Mustard Compounds results in decreased expression of BRCA1 mRNA Cycloheximide inhibits the reaction [Nitrogen Mustard Compounds results in decreased expression of BRCA1 mRNA] |
CTD |
PMID:10344722 |
|
NCBI chr10:89,394,821...89,455,093
Ensembl chr10:89,394,803...89,454,681
|
|
G |
Brca2 |
BRCA2, DNA repair associated |
multiple interactions increases expression decreases expression |
ISO |
Cycloheximide inhibits the reaction [Nitrogen Mustard Compounds results in decreased expression of BRCA2 mRNA] Nitrogen Mustard Compounds results in increased expression of BRCA2 mRNA |
CTD |
PMID:10344722 PMID:27342729 |
|
NCBI chr12:503,660...544,754
Ensembl chr12:504,007...544,748
|
|
G |
Cdh2 |
cadherin 2 |
decreases expression multiple interactions |
ISO |
Nitrogen Mustard Compounds results in decreased expression of CDH2 mRNA; Nitrogen Mustard Compounds results in decreased expression of CDH2 protein Plant Extracts inhibits the reaction [Nitrogen Mustard Compounds results in decreased expression of CDH2 mRNA]; Plant Extracts inhibits the reaction [Nitrogen Mustard Compounds results in decreased expression of CDH2 protein] |
CTD |
PMID:18572855 |
|
NCBI chr18:8,146,971...8,366,037
Ensembl chr18:8,146,971...8,360,684
|
|
G |
Dhfr |
dihydrofolate reductase |
decreases response to substance |
ISO |
DHFR protein polymorphism results in decreased susceptibility to Nitrogen Mustard Compounds |
CTD |
PMID:12872145 |
|
NCBI chr 2:21,931,887...21,958,927
Ensembl chr 2:21,931,493...21,962,453
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
decreases expression |
ISO |
Nitrogen Mustard Compounds results in decreased expression of ERBB2 mRNA |
CTD |
PMID:16417271 |
|
NCBI chr10:86,367,596...86,391,728
Ensembl chr10:86,367,596...86,391,728
|
|
G |
Fancd2 |
FA complementation group D2 |
increases expression |
ISO |
Nitrogen Mustard Compounds results in increased expression of FANCD2 mRNA; Nitrogen Mustard Compounds results in increased expression of FANCD2 protein |
CTD |
PMID:27342729 |
|
NCBI chr 4:145,489,869...145,551,479
Ensembl chr 4:145,489,869...145,551,479
|
|
G |
Gsta3 |
glutathione S-transferase alpha 3 |
decreases response to substance |
EXP |
GSTA3 protein results in decreased susceptibility to Nitrogen Mustard Compounds |
CTD |
PMID:9414483 PMID:12872145 |
|
NCBI chr 9:27,357,490...27,417,023
Ensembl chr 9:27,402,381...27,417,023
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions increases expression |
ISO |
MGMT protein affects the reaction [Nitrogen Mustard Compounds results in increased expression of H2AX protein]; Nitrogen Mustard Compounds results in decreased expression of and results in increased phosphorylation of H2AX protein Nitrogen Mustard Compounds results in increased expression of H2AX mRNA; Nitrogen Mustard Compounds results in increased expression of H2AX protein |
CTD |
PMID:27342729 |
|
NCBI chr 8:48,665,652...48,666,981
Ensembl chr 8:48,665,652...48,666,981
|
|
G |
Igf1r |
insulin-like growth factor 1 receptor |
affects response to substance |
ISO |
IGF1R protein affects the susceptibility to Nitrogen Mustard Compounds |
CTD |
PMID:15499378 |
|
NCBI chr 1:128,924,921...129,213,816
Ensembl chr 1:128,924,966...129,206,516
|
|
G |
Mgmt |
O-6-methylguanine-DNA methyltransferase |
multiple interactions decreases expression |
ISO |
MGMT protein affects the reaction [Nitrogen Mustard Compounds results in increased expression of H2AX protein]; MGMT protein affects the reaction [Nitrogen Mustard Compounds results in increased expression of SPRTN protein] Nitrogen Mustard Compounds results in decreased expression of MGMT mRNA |
CTD |
PMID:27342729 |
|
NCBI chr 1:209,237,255...209,464,189
Ensembl chr 1:209,237,233...209,464,190
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
increases expression multiple interactions |
ISO |
Nitrogen Mustard Compounds results in increased expression of NFE2L2 protein caffeic acid phenethyl ester promotes the reaction [Nitrogen Mustard Compounds results in increased expression of NFE2L2 protein] |
CTD |
PMID:17204746 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
increases degradation |
ISO |
Nitrogen Mustard Compounds results in increased degradation of NFKBIA protein |
CTD |
PMID:17204746 |
|
NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
|
|
G |
Rps6ka2 |
ribosomal protein S6 kinase A2 |
multiple interactions increases phosphorylation |
ISO |
caffeic acid phenethyl ester inhibits the reaction [Nitrogen Mustard Compounds results in increased phosphorylation of RPS6KA2 protein] |
CTD |
PMID:17204746 |
|
NCBI chr 1:53,219,346...53,499,445
Ensembl chr 1:53,360,157...53,499,445
|
|
G |
Sprtn |
SprT-like N-terminal domain |
multiple interactions increases expression |
ISO |
MGMT protein affects the reaction [Nitrogen Mustard Compounds results in increased expression of SPRTN protein] Nitrogen Mustard Compounds results in increased expression of SPRTN mRNA; Nitrogen Mustard Compounds results in increased expression of SPRTN protein |
CTD |
PMID:27342729 |
|
NCBI chr19:57,649,901...57,657,158
Ensembl chr19:57,650,163...57,654,864
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions increases phosphorylation |
ISO |
caffeic acid phenethyl ester inhibits the reaction [Nitrogen Mustard Compounds results in increased phosphorylation of TP53 protein] |
CTD |
PMID:17204746 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
G |
Vim |
vimentin |
decreases expression |
ISO |
Nitrogen Mustard Compounds results in decreased expression of VIM mRNA; Nitrogen Mustard Compounds results in decreased expression of VIM protein |
CTD |
PMID:17192600 |
|
NCBI chr17:80,882,715...80,891,200
Ensembl chr17:80,882,666...80,891,212
|
|
G |
Xrcc5 |
X-ray repair cross complementing 5 |
affects response to substance |
ISO |
XRCC5 protein affects the susceptibility to Nitrogen Mustard Compounds |
CTD |
PMID:10717383 |
|
NCBI chr 9:79,659,275...79,748,050
Ensembl chr 9:79,659,251...79,748,078
|
|
|
G |
Abl1 |
ABL proto-oncogene 1, non-receptor tyrosine kinase |
increases expression |
ISO |
perfosfamide results in increased expression of ABL1 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 3:10,041,820...10,145,076
Ensembl chr 3:10,041,826...10,144,388
|
|
G |
Actb |
actin, beta |
decreases expression |
ISO |
perfosfamide results in decreased expression of ACTB mRNA |
CTD |
PMID:19429390 |
|
NCBI chr12:13,715,843...13,718,813
Ensembl chr12:13,715,843...13,718,841
|
|
G |
Agt |
angiotensinogen |
decreases response to substance |
ISO |
AGT protein results in decreased susceptibility to perfosfamide |
CTD |
PMID:11034089 |
|
NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
multiple interactions increases response to substance |
ISO |
Acetylcysteine inhibits the reaction [perfosfamide results in increased localization of AIFM1 protein]; perfosfamide results in increased expression of and results in increased localization of AIFM1 protein AIFM1 results in increased susceptibility to perfosfamide |
CTD |
PMID:18034189 |
|
NCBI chr X:135,304,063...135,343,062
Ensembl chr X:135,304,066...135,343,087
|
|
G |
Akr1b10 |
aldo-keto reductase family 1 member B10 |
affects response to substance |
ISO |
AKR1B10 protein affects the susceptibility to perfosfamide |
CTD |
PMID:18473730 |
|
NCBI chr 4:61,813,265...61,830,371
Ensembl chr 4:61,771,970...61,828,657
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
decreases response to substance |
ISO |
ALDH1A1 protein results in decreased susceptibility to perfosfamide |
CTD |
PMID:8662658 PMID:16614850 |
|
NCBI chr 1:238,222,689...238,264,381
Ensembl chr 1:238,222,521...238,264,330
|
|
G |
Aldh1a2 |
aldehyde dehydrogenase 1 family, member A2 |
decreases response to substance |
ISO |
ALDH1A2 protein results in decreased susceptibility to perfosfamide |
CTD |
PMID:22079344 |
|
NCBI chr 8:77,640,234...77,719,488
Ensembl chr 8:77,640,222...77,719,489
|
|
G |
Aldh1b1 |
aldehyde dehydrogenase 1 family, member B1 |
affects response to substance |
ISO |
ALDH1B1 protein affects the susceptibility to perfosfamide |
CTD |
PMID:18473730 |
|
NCBI chr 5:61,382,351...61,387,359
Ensembl chr 5:61,382,351...61,387,358
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2 family member |
decreases response to substance |
ISO |
ALDH2 protein results in decreased susceptibility to perfosfamide |
CTD |
PMID:22079344 |
|
NCBI chr12:40,466,418...40,498,813
Ensembl chr12:40,466,495...40,498,752
|
|
G |
Aldh3a1 |
aldehyde dehydrogenase 3 family, member A1 |
decreases response to substance |
ISO |
ALDH3A1 protein results in decreased susceptibility to perfosfamide |
CTD |
PMID:16614850 |
|
NCBI chr10:47,490,168...47,499,855
Ensembl chr10:47,490,153...47,499,876
|
|
G |
Apex1 |
apurinic/apyrimidinic endodeoxyribonuclease 1 |
decreases expression |
EXP |
perfosfamide results in decreased expression of APEX1 mRNA |
CTD |
PMID:11754170 |
|
NCBI chr15:27,849,943...27,852,083
Ensembl chr15:27,849,979...27,852,082
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions affects folding increases expression |
ISO |
Acetylcysteine inhibits the reaction [perfosfamide affects the folding of BAX protein]; Acetylcysteine inhibits the reaction [perfosfamide results in increased localization of BAX]; perfosfamide results in increased expression of and results in increased localization of BAX perfosfamide results in increased expression of BAX protein |
CTD |
PMID:16488414 PMID:18034189 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
increases expression |
ISO |
perfosfamide results in increased expression of BBC3 mRNA |
CTD |
PMID:17068108 |
|
NCBI chr 1:78,261,491...78,267,802
|
|
G |
Bmpr1b |
bone morphogenetic protein receptor type 1B |
decreases expression |
ISO |
perfosfamide results in decreased expression of BMPR1B mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 2:247,392,195...247,662,026
Ensembl chr 2:247,403,920...247,446,882
|
|
G |
C1d |
C1D nuclear receptor corepressor |
increases expression |
ISO |
perfosfamide results in increased expression of C1D mRNA |
CTD |
PMID:19429390 |
|
NCBI chr14:100,415,645...100,427,878
Ensembl chr14:100,415,668...100,427,260
|
|
G |
Casp3 |
caspase 3 |
increases activity multiple interactions |
ISO |
perfosfamide results in increased activity of CASP3 perfosfamide promotes the reaction [TNF results in increased activity of CASP3 protein] |
CTD |
PMID:16488414 PMID:17434952 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp9 |
caspase 9 |
increases activity |
ISO |
perfosfamide results in increased activity of CASP9 protein |
CTD |
PMID:16488414 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
perfosfamide results in increased expression of CDKN1A perfosfamide results in increased expression of CDKN1A mRNA; perfosfamide results in increased expression of CDKN1A protein |
CTD |
PMID:17068108 PMID:18034189 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cxcl9 |
C-X-C motif chemokine ligand 9 |
decreases expression |
ISO |
perfosfamide results in decreased expression of CXCL9 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr14:17,228,832...17,233,743
Ensembl chr14:17,228,856...17,234,712
|
|
G |
E2f1 |
E2F transcription factor 1 |
increases expression |
ISO |
perfosfamide results in increased expression of E2F1 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 3:150,062,895...150,073,721
Ensembl chr 3:150,047,826...150,073,721
|
|
G |
Egr1 |
early growth response 1 |
decreases expression |
ISO |
perfosfamide results in decreased expression of EGR1 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr18:27,657,903...27,660,101
Ensembl chr18:27,657,628...27,661,429
|
|
G |
Endog |
endonuclease G |
increases response to substance multiple interactions |
ISO |
ENDOG results in increased susceptibility to perfosfamide Acetylcysteine inhibits the reaction [perfosfamide results in increased localization of ENDOG protein]; perfosfamide results in increased expression of and results in increased localization of ENDOG protein |
CTD |
PMID:18034189 |
|
NCBI chr 3:8,741,833...8,744,414
Ensembl chr 3:8,741,766...8,744,592
|
|
G |
Epas1 |
endothelial PAS domain protein 1 |
increases expression |
ISO |
perfosfamide results in increased expression of EPAS1 protein |
CTD |
PMID:23251655 |
|
NCBI chr 6:10,306,508...10,385,239
Ensembl chr 6:10,306,405...10,387,265
|
|
G |
Epha6 |
Eph receptor A6 |
decreases expression |
ISO |
perfosfamide results in decreased expression of EPHA6 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr11:41,867,607...42,843,800
|
|
G |
Eya1 |
EYA transcriptional coactivator and phosphatase 1 |
decreases expression |
ISO |
perfosfamide results in decreased expression of EYA1 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 5:4,275,728...4,495,525
Ensembl chr 5:4,373,626...4,513,142
|
|
G |
Faslg |
Fas ligand |
increases expression |
ISO |
perfosfamide results in increased expression of FASLG mRNA; perfosfamide results in increased expression of FASLG protein |
CTD |
PMID:14760101 |
|
NCBI chr13:79,696,811...79,717,581
Ensembl chr13:79,698,445...79,705,705
|
|
G |
Foxf1 |
forkhead box F1 |
affects expression |
ISO |
perfosfamide affects the expression of FOXF1 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr19:53,012,306...53,016,100
Ensembl chr19:53,012,332...53,016,086
|
|
G |
Gjc1 |
gap junction protein, gamma 1 |
increases expression |
ISO |
perfosfamide results in increased expression of GJC1 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr10:90,781,408...90,912,440
Ensembl chr10:90,781,402...90,912,287
|
|
G |
Gli2 |
GLI family zinc finger 2 |
decreases expression |
ISO |
perfosfamide results in decreased expression of GLI2 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr13:34,829,021...35,049,172
Ensembl chr13:34,829,139...35,048,444
|
|
G |
Hes1 |
hes family bHLH transcription factor 1 |
increases expression |
ISO |
perfosfamide results in increased expression of HES1 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr11:74,312,837...74,315,249
Ensembl chr11:74,312,806...74,315,248
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
increases expression |
ISO |
perfosfamide results in increased expression of HIF1A mRNA; perfosfamide results in increased expression of HIF1A protein |
CTD |
PMID:19429390 PMID:23251655 |
|
NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
|
|
G |
Hoxa11 |
homeobox A11 |
decreases expression |
ISO |
perfosfamide results in decreased expression of HOXA11 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 4:82,296,888...82,301,419
Ensembl chr 4:82,298,152...82,300,503 Ensembl chr 4:82,298,152...82,300,503
|
|
G |
Hoxa13 |
homeo box A13 |
increases expression |
ISO |
perfosfamide results in increased expression of HOXA13 mRNA |
CTD |
PMID:19429390 |
|
Ensembl chr 4:82,228,017...82,229,397
|
|
G |
Hoxd10 |
homeo box D10 |
increases expression |
ISO |
perfosfamide results in increased expression of HOXD10 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 3:61,614,133...61,617,342
Ensembl chr 3:61,613,774...61,617,367
|
|
G |
Hras |
HRas proto-oncogene, GTPase |
decreases expression |
ISO |
perfosfamide results in decreased expression of HRAS mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 1:214,178,404...214,181,841
Ensembl chr 1:214,178,407...214,181,686
|
|
G |
Kl |
Klotho |
decreases expression |
ISO |
perfosfamide results in decreased expression of KL mRNA |
CTD |
PMID:19429390 |
|
NCBI chr12:942,974...987,206
Ensembl chr12:943,006...987,551
|
|
G |
Lig3 |
DNA ligase 3 |
decreases expression |
EXP |
perfosfamide results in decreased expression of LIG3 mRNA |
CTD |
PMID:11754170 |
|
NCBI chr10:70,134,734...70,158,051
Ensembl chr10:70,134,729...70,158,055
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
increases expression |
ISO |
perfosfamide results in increased expression of MDM2 |
CTD |
PMID:18034189 |
|
NCBI chr 7:60,719,060...60,743,618
Ensembl chr 7:60,719,066...60,743,328
|
|
G |
Mgmt |
O-6-methylguanine-DNA methyltransferase |
decreases expression |
EXP |
perfosfamide results in decreased expression of MGMT mRNA |
CTD |
PMID:11754170 |
|
NCBI chr 1:209,237,255...209,464,189
Ensembl chr 1:209,237,233...209,464,190
|
|
G |
Mlh1 |
mutL homolog 1 |
decreases expression |
EXP |
perfosfamide results in decreased expression of MLH1 mRNA |
CTD |
PMID:11754170 |
|
NCBI chr 8:119,486,655...119,523,716
Ensembl chr 8:119,486,691...119,523,964
|
|
G |
Mpg |
N-methylpurine-DNA glycosylase |
decreases expression |
EXP |
perfosfamide results in decreased expression of MPG mRNA |
CTD |
PMID:11754170 |
|
NCBI chr10:15,661,768...15,667,995
Ensembl chr10:15,661,608...15,668,022
|
|
G |
Mre11 |
MRE11 homolog, double strand break repair nuclease |
decreases expression |
EXP |
perfosfamide results in decreased expression of MRE11A mRNA |
CTD |
PMID:11754170 |
|
NCBI chr 8:13,304,355...13,350,329
Ensembl chr 8:13,305,152...13,352,489
|
|
G |
Myo1b |
myosin Ib |
increases expression |
ISO |
perfosfamide results in increased expression of MYO1B mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 9:54,706,005...54,766,054
Ensembl chr 9:54,558,202...54,766,054
|
|
G |
Myog |
myogenin |
increases expression |
ISO |
perfosfamide results in increased expression of MYOG mRNA |
CTD |
PMID:19429390 |
|
NCBI chr13:51,126,459...51,129,048
Ensembl chr13:51,126,459...51,129,048
|
|
G |
Ndn |
necdin, MAGE family member |
increases expression |
ISO |
perfosfamide results in increased expression of NDN mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 1:122,981,755...122,983,354
Ensembl chr 1:122,981,755...122,983,351
|
|
G |
Odc1 |
ornithine decarboxylase 1 |
decreases expression |
ISO |
perfosfamide results in decreased expression of ODC1 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 6:42,852,529...42,859,142
Ensembl chr 6:42,852,683...42,859,927
|
|
G |
Pea15 |
proliferation and apoptosis adaptor protein 15 |
decreases expression |
ISO |
perfosfamide results in decreased expression of PEA15 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr13:90,579,844...90,589,466
Ensembl chr13:90,579,846...90,589,466
|
|
G |
Pmaip1 |
phorbol-12-myristate-13-acetate-induced protein 1 |
increases expression |
ISO |
perfosfamide results in increased expression of PMAIP1 mRNA |
CTD |
PMID:17068108 |
|
NCBI chr18:62,159,128...62,179,635
Ensembl chr18:62,174,670...62,181,102
|
|
G |
Pms1 |
PMS1 homolog 1, mismatch repair system component |
decreases expression |
EXP |
perfosfamide results in decreased expression of PMS1 mRNA |
CTD |
PMID:11754170 |
|
NCBI chr 9:53,120,656...53,206,520
Ensembl chr 9:53,120,656...53,206,516
|
|
G |
Pms2 |
PMS1 homolog 2, mismatch repair system component |
decreases expression |
EXP |
perfosfamide results in decreased expression of PMS2 mRNA |
CTD |
PMID:11754170 |
|
NCBI chr12:12,714,394...12,738,654
Ensembl chr12:12,714,394...12,738,641
|
|
G |
Polb |
DNA polymerase beta |
decreases expression |
EXP |
perfosfamide results in decreased expression of POLB mRNA |
CTD |
PMID:11754170 |
|
NCBI chr16:74,237,001...74,260,272
Ensembl chr16:74,237,001...74,260,271
|
|
G |
Pold1 |
DNA polymerase delta 1, catalytic subunit |
decreases expression |
ISO |
perfosfamide results in decreased expression of POLD1 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 1:100,538,066...100,554,105
Ensembl chr 1:100,537,900...100,554,488
|
|
G |
Rad21 |
RAD21 cohesin complex component |
decreases expression |
ISO |
perfosfamide results in decreased expression of RAD21 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 7:91,511,755...91,538,673
Ensembl chr 7:91,511,756...91,538,673
|
|
G |
Rad50 |
RAD50 double strand break repair protein |
decreases expression |
EXP |
perfosfamide results in decreased expression of RAD50 mRNA |
CTD |
PMID:11754170 |
|
NCBI chr10:39,002,130...39,054,042
Ensembl chr10:39,001,498...39,054,142
|
|
G |
Rad51 |
RAD51 recombinase |
decreases expression |
EXP |
perfosfamide results in decreased expression of RAD51 mRNA |
CTD |
PMID:11754170 |
|
NCBI chr 3:110,918,240...110,942,920
Ensembl chr 3:110,918,243...110,942,917
|
|
G |
Sdf4 |
stromal cell derived factor 4 |
decreases expression |
ISO |
perfosfamide results in decreased expression of SDF4 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 5:173,425,922...173,444,478
Ensembl chr 5:173,425,907...173,444,620
|
|
G |
Sfrp2 |
secreted frizzled-related protein 2 |
decreases expression |
ISO |
perfosfamide results in decreased expression of SFRP2 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 2:182,723,732...182,731,277
Ensembl chr 2:182,723,854...182,731,764
|
|
G |
Slc30a4 |
solute carrier family 30 member 4 |
decreases expression |
ISO |
perfosfamide results in decreased expression of SLC30A4 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 3:114,805,919...114,828,154
Ensembl chr 3:114,805,922...114,828,154
|
|
G |
Smad1 |
SMAD family member 1 |
decreases expression |
ISO |
perfosfamide results in decreased expression of SMAD1 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr19:32,182,942...32,248,694
Ensembl chr19:32,188,267...32,248,684
|
|
G |
Tap1 |
transporter 1, ATP binding cassette subfamily B member |
affects response to substance |
ISO |
TAP1 protein affects the susceptibility to perfosfamide |
CTD |
PMID:18473730 |
|
NCBI chr20:3,979,302...3,989,669
Ensembl chr20:3,979,035...3,989,669
|
|
G |
Tcf12 |
transcription factor 12 |
increases expression |
ISO |
perfosfamide results in increased expression of TCF12 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 8:78,343,634...78,657,738
Ensembl chr 8:78,345,754...78,655,856
|
|
G |
Terc |
telomerase RNA component |
decreases expression |
ISO |
perfosfamide results in decreased expression of TERC mRNA |
CTD |
PMID:24571982 |
|
NCBI chr 2:116,432,723...116,433,110
Ensembl chr 2:116,432,691...116,433,110
|
|
G |
Tert |
telomerase reverse transcriptase |
decreases expression |
ISO |
perfosfamide results in decreased expression of TERT mRNA |
CTD |
PMID:24571982 |
|
NCBI chr 1:32,250,876...32,275,330
Ensembl chr 1:32,251,714...32,272,476
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
perfosfamide promotes the reaction [TNF results in increased activity of CASP3 protein] |
CTD |
PMID:16488414 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions increases expression |
ISO |
Acetylcysteine inhibits the reaction [perfosfamide results in increased expression of TP53] perfosfamide results in increased expression of and results in increased phosphorylation of and results in increased activity of TRP53 protein |
CTD |
PMID:17068108 PMID:18034189 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
G |
Trim27 |
tripartite motif-containing 27 |
decreases expression |
ISO |
perfosfamide results in decreased expression of TRIM27 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr17:45,613,863...45,626,212
Ensembl chr17:45,613,864...45,626,212
|
|
G |
Ttf1 |
transcription termination factor 1 |
decreases expression |
ISO |
perfosfamide results in decreased expression of TTF1 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 3:7,635,630...7,660,153
Ensembl chr 3:7,635,933...7,660,673
|
|
G |
Ubb |
ubiquitin B |
decreases expression |
ISO |
perfosfamide results in decreased expression of UBB mRNA |
CTD |
PMID:19429390 |
|
NCBI chr10:48,880,231...48,881,896
Ensembl chr10:48,881,049...48,881,881
|
|
G |
Vegfa |
vascular endothelial growth factor A |
increases expression |
ISO |
perfosfamide results in increased expression of VEGFA mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
G |
Vim |
vimentin |
decreases expression |
ISO |
perfosfamide results in decreased expression of VIM mRNA |
CTD |
PMID:19429390 |
|
NCBI chr17:80,882,715...80,891,200
Ensembl chr17:80,882,666...80,891,212
|
|
G |
Wnt11 |
Wnt family member 11 |
increases expression |
ISO |
perfosfamide results in increased expression of WNT11 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 1:163,794,136...163,813,756
Ensembl chr 1:163,797,660...163,813,756
|
|
G |
Xrcc1 |
X-ray repair cross complementing 1 |
decreases expression |
EXP |
perfosfamide results in decreased expression of XRCC1 mRNA |
CTD |
PMID:11754170 |
|
NCBI chr 1:81,412,635...81,441,680
Ensembl chr 1:81,413,353...81,441,678
|
|
G |
Xrcc5 |
X-ray repair cross complementing 5 |
decreases expression |
EXP |
perfosfamide results in decreased expression of XRCC5 mRNA |
CTD |
PMID:11754170 |
|
NCBI chr 9:79,659,275...79,748,050
Ensembl chr 9:79,659,251...79,748,078
|
|
G |
Ywhaz |
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta |
decreases expression |
ISO |
perfosfamide results in decreased expression of YWHAZ mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 7:75,573,553...75,598,295
Ensembl chr 7:75,574,967...75,597,276
|
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
multiple interactions |
EXP |
[afimoxifene co-treated with 4-hydroxycyclophosphamide] affects the expression of ALOX5 mRNA |
CTD |
PMID:25833159 |
|
NCBI chr 4:148,398,004...148,446,308
Ensembl chr 4:148,398,892...148,446,303
|
|
G |
Bdkrb2 |
bradykinin receptor B2 |
multiple interactions |
EXP |
[afimoxifene co-treated with 4-hydroxycyclophosphamide] affects the expression of BDKRB2 mRNA |
CTD |
PMID:25833159 |
|
NCBI chr 6:129,399,468...129,429,676
Ensembl chr 6:129,399,468...129,429,676
|
|
G |
Cd40 |
CD40 molecule |
multiple interactions |
EXP |
[afimoxifene co-treated with 4-hydroxycyclophosphamide] affects the expression of CD40 mRNA |
CTD |
PMID:25833159 |
|
NCBI chr 3:161,519,789...161,534,943
Ensembl chr 3:161,519,743...161,534,704
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
increases chemical synthesis |
ISO |
CYP2B6 protein results in increased chemical synthesis of 4-hydroxycyclophosphamide |
CTD |
PMID:24819615 |
|
NCBI chr 1:83,163,103...83,236,615
Ensembl chr 1:83,163,079...83,236,615
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
increases chemical synthesis |
ISO |
CYP2C9 protein results in increased chemical synthesis of 4-hydroxycyclophosphamide |
CTD |
PMID:24819615 |
|
NCBI chr 1:257,676,172...258,004,428
Ensembl chr 1:257,970,345...258,004,434
|
|
G |
Cyp2c6v1 |
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 |
multiple interactions |
ISO |
[CYP2C19 protein results in increased hydroxylation of Cyclophosphamide] which results in increased chemical synthesis of 4-hydroxycyclophosphamide |
CTD |
PMID:30500380 |
|
NCBI chr 1:147,713,879...147,814,410
Ensembl chr 1:147,713,892...147,888,007
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
multiple interactions |
ISO |
[CYP3A4 protein results in increased hydroxylation of Cyclophosphamide] which results in increased chemical synthesis of 4-hydroxycyclophosphamide |
CTD |
PMID:30500380 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Il1r1 |
interleukin 1 receptor type 1 |
multiple interactions |
EXP |
[afimoxifene co-treated with 4-hydroxycyclophosphamide] affects the expression of IL1R1 mRNA |
CTD |
PMID:25833159 |
|
NCBI chr 9:46,962,291...47,038,139
Ensembl chr 9:46,962,288...47,036,670
|
|
G |
Il2rg |
interleukin 2 receptor subunit gamma |
multiple interactions |
EXP |
[afimoxifene co-treated with 4-hydroxycyclophosphamide] affects the expression of IL2RG mRNA |
CTD |
PMID:25833159 |
|
NCBI chr X:71,165,378...71,169,078
Ensembl chr X:71,162,585...71,169,865
|
|
G |
Klk15 |
kallikrein-related peptidase 15 |
multiple interactions |
EXP |
[afimoxifene co-treated with 4-hydroxycyclophosphamide] affects the expression of KLK15 mRNA |
CTD |
PMID:25833159 |
|
NCBI chr 1:99,393,283...99,401,339
Ensembl chr 1:99,398,248...99,401,126 Ensembl chr 1:99,398,248...99,401,126
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions |
EXP |
[afimoxifene co-treated with 4-hydroxycyclophosphamide] affects the expression of MAPK14 mRNA |
CTD |
PMID:25833159 |
|
NCBI chr20:5,933,290...5,995,137
Ensembl chr20:5,933,303...5,995,137
|
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
multiple interactions increases oxidation |
ISO |
[ALDH1A1 protein co-treated with NAD] results in increased oxidation of aldophosphamide ALDH1A1 results in increased oxidation of aldophosphamide |
CTD |
PMID:8662658 PMID:10856427 |
|
NCBI chr 1:238,222,689...238,264,381
Ensembl chr 1:238,222,521...238,264,330
|
|
G |
Aldh3a1 |
aldehyde dehydrogenase 3 family, member A1 |
multiple interactions |
ISO |
[ALDH3A1 protein co-treated with NAD] results in increased oxidation of aldophosphamide; [ALDH3A1 protein co-treated with NADP] results in increased oxidation of aldophosphamide |
CTD |
PMID:10856427 |
|
NCBI chr10:47,490,168...47,499,855
Ensembl chr10:47,490,153...47,499,876
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases expression |
ISO |
Chlorambucil results in increased expression of ABCB1 protein |
CTD |
PMID:15239124 |
|
NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
affects export decreases response to substance increases response to substance multiple interactions |
ISO |
ABCC1 protein affects the export of Chlorambucil analog ABCC1 protein results in decreased susceptibility to Chlorambucil ABCC1 protein results in increased susceptibility to Chlorambucil buthionine sulfoximine ethyl ester promotes the reaction [ABCC1 protein results in increased susceptibility to Chlorambucil]; GSTP1 protein promotes the reaction [ABCC1 protein results in decreased susceptibility to Chlorambucil] |
CTD |
PMID:10900222 PMID:11115505 PMID:12504668 PMID:14569069 |
|
NCBI chr10:549,537...672,235
Ensembl chr10:549,883...672,196
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
affects export multiple interactions |
ISO |
ABCC2 protein affects the export of Chlorambucil analog ABCC2 protein promotes the reaction [GSTA1 protein results in decreased susceptibility to Chlorambucil] |
CTD |
PMID:14569069 |
|
NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252
|
|
G |
Akr1b10 |
aldo-keto reductase family 1 member B10 |
decreases expression |
ISO |
Chlorambucil results in decreased expression of AKR1B10 mRNA |
CTD |
PMID:26198647 |
|
NCBI chr 4:61,813,265...61,830,371
Ensembl chr 4:61,771,970...61,828,657
|
|
G |
Akr1c2 |
aldo-keto reductase family 1, member C2 |
decreases expression |
ISO |
Chlorambucil results in decreased expression of AKR1C2 mRNA |
CTD |
PMID:26198647 |
|
NCBI chr17:69,388,337...69,435,160
Ensembl chr17:69,388,335...69,404,341
|
|
G |
Asf1a |
anti-silencing function 1A histone chaperone |
decreases expression |
ISO |
Chlorambucil results in decreased expression of ASF1A mRNA |
CTD |
PMID:26198647 |
|
NCBI chr20:34,894,419...34,909,265
Ensembl chr20:34,894,419...34,909,265
|
|
G |
Aurka |
aurora kinase A |
increases expression |
ISO |
Chlorambucil results in increased expression of AURKA protein |
CTD |
PMID:22025197 |
|
NCBI chr 3:170,364,177...170,380,278
Ensembl chr 3:170,364,181...170,378,210
|
|
G |
Aurkb |
aurora kinase B |
decreases expression |
ISO |
Chlorambucil results in decreased expression of AURKB protein |
CTD |
PMID:22025197 |
|
NCBI chr10:55,625,860...55,632,399
Ensembl chr10:55,626,741...55,634,991
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
Chlorambucil results in increased expression of BAX protein |
CTD |
PMID:11699414 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
increases expression |
ISO |
Chlorambucil results in increased expression of BBC3 mRNA |
CTD |
PMID:17476690 |
|
NCBI chr 1:78,261,491...78,267,802
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression multiple interactions |
ISO |
Chlorambucil results in decreased expression of BCL2 mRNA; Chlorambucil results in decreased expression of BCL2 protein IL4 protein inhibits the reaction [Chlorambucil results in decreased expression of BCL2 protein] |
CTD |
PMID:8822937 PMID:11699414 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bik |
BCL2-interacting killer |
increases expression |
ISO |
Chlorambucil results in increased expression of BIK mRNA |
CTD |
PMID:26198647 |
|
NCBI chr 7:124,390,924...124,410,449
Ensembl chr 7:124,391,432...124,410,447
|
|
G |
Birc2 |
baculoviral IAP repeat-containing 2 |
decreases response to substance |
ISO |
BIRC2 protein results in decreased susceptibility to Chlorambucil |
CTD |
PMID:10815900 |
|
NCBI chr 8:6,014,014...6,036,668
Ensembl chr 8:6,013,207...6,034,142
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
affects expression decreases expression |
ISO |
Chlorambucil affects the expression of BIRC5 mRNA Chlorambucil results in decreased expression of BIRC5 protein |
CTD |
PMID:17476690 PMID:22025197 |
|
NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413
|
|
G |
Bmp5 |
bone morphogenetic protein 5 |
increases mutagenesis |
ISO |
Chlorambucil results in increased mutagenesis of BMP5 gene |
CTD |
PMID:10517996 |
|
NCBI chr 8:82,669,466...82,950,273
Ensembl chr 8:82,878,941...82,950,273
|
|
G |
Casp3 |
caspase 3 |
increases activity |
ISO |
Chlorambucil results in increased activity of CASP3 protein |
CTD |
PMID:11675354 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp8 |
caspase 8 |
increases activity |
ISO |
Chlorambucil results in increased activity of CASP8 protein |
CTD |
PMID:11675354 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Cd59 |
CD59 molecule |
decreases lipidation |
EXP |
Chlorambucil results in decreased lipidation of CD59 protein |
CTD |
PMID:27931811 |
|
NCBI chr 3:94,010,481...94,028,660
Ensembl chr 3:94,010,475...94,028,621
|
|
G |
Cda |
cytidine deaminase |
decreases response to substance |
ISO |
CDA protein results in decreased susceptibility to Chlorambucil |
CTD |
PMID:10830723 |
|
NCBI chr 5:156,703,579...156,734,541
Ensembl chr 5:156,703,579...156,734,541
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
multiple interactions |
ISO |
Chlorambucil analog results in increased phosphorylation of and results in decreased activity of CDK1 protein |
CTD |
PMID:16861886 |
|
NCBI chr20:20,576,341...20,591,510
Ensembl chr20:20,576,377...20,591,549
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
Chlorambucil results in increased expression of CDKN1A protein |
CTD |
PMID:16039525 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Dhfr |
dihydrofolate reductase |
decreases response to substance |
ISO |
DHFR protein polymorphism results in decreased susceptibility to Chlorambucil |
CTD |
PMID:12872145 |
|
NCBI chr 2:21,931,887...21,958,927
Ensembl chr 2:21,931,493...21,962,453
|
|
G |
Ednrb |
endothelin receptor type B |
increases mutagenesis |
ISO |
Chlorambucil results in increased mutagenesis of EDNRB gene |
CTD |
PMID:10517996 |
|
NCBI chr15:88,004,775...88,036,354
Ensembl chr15:88,006,977...88,036,354
|
|
G |
Fancc |
FA complementation group C |
increases response to substance |
ISO |
FANCC protein results in increased susceptibility to Chlorambucil |
CTD |
PMID:16243825 |
|
NCBI chr17:826,512...955,703
Ensembl chr17:833,509...955,615
|
|
G |
Fancg |
FA complementation group G |
increases response to substance |
ISO |
FANCG protein results in increased susceptibility to Chlorambucil |
CTD |
PMID:16243825 |
|
NCBI chr 5:58,448,060...58,456,416
Ensembl chr 5:58,448,822...58,455,819
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression |
ISO |
Chlorambucil results in increased expression of FAS mRNA |
CTD |
PMID:11675354 PMID:17476690 |
|
NCBI chr 1:252,589,785...252,624,790
Ensembl chr 1:252,589,785...252,624,790
|
|
G |
Fbxo30 |
F-box protein 30 |
decreases expression |
ISO |
Chlorambucil results in decreased expression of FBXO30 mRNA |
CTD |
PMID:26198647 |
|
NCBI chr 1:5,366,119...5,389,774
Ensembl chr 1:5,366,379...5,388,069
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions |
ISO |
[GCLC protein co-treated with GCLM protein] results in decreased susceptibility to Chlorambucil |
CTD |
PMID:10900222 |
|
NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
multiple interactions |
ISO |
[GCLC protein co-treated with GCLM protein] results in decreased susceptibility to Chlorambucil |
CTD |
PMID:10900222 |
|
NCBI chr 2:225,827,504...225,847,876
Ensembl chr 2:225,827,504...225,847,874
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
decreases activity decreases response to substance multiple interactions |
ISO |
Chlorambucil analog results in decreased activity of GSTA1 protein GSTA1 protein results in decreased susceptibility to Chlorambucil ABCC2 protein promotes the reaction [GSTA1 protein results in decreased susceptibility to Chlorambucil]; GSTA1 protein affects the metabolism of [Chlorambucil co-treated with Glutathione] |
CTD |
PMID:11115505 PMID:14569069 |
|
NCBI chr 9:27,366,404...27,381,004
Ensembl chr 9:27,368,272...27,452,902
|
|
G |
Gsta3 |
glutathione S-transferase alpha 3 |
decreases response to substance |
EXP |
GSTA3 protein results in decreased susceptibility to Chlorambucil |
CTD |
PMID:8044793 PMID:8860835 PMID:10830723 PMID:12872145 |
|
NCBI chr 9:27,357,490...27,417,023
Ensembl chr 9:27,402,381...27,417,023
|
|
G |
Gsta5 |
glutathione S-transferase alpha 5 |
decreases response to substance |
EXP |
GSTA5 protein results in decreased susceptibility to Chlorambucil |
CTD |
PMID:12076520 |
|
NCBI chr 8:85,553,659...85,564,914
Ensembl chr 8:85,553,734...85,565,179
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
decreases response to substance |
ISO |
GSTM1 protein results in decreased susceptibility to Chlorambucil |
CTD |
PMID:15044619 PMID:20067466 |
|
NCBI chr 2:210,803,869...210,809,461
Ensembl chr 2:210,803,869...210,809,306
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
affects binding increases metabolic processing decreases response to substance affects response to substance multiple interactions |
ISO |
Chlorambucil binds to GSTP1 protein GSTP1 protein results in increased metabolism of Chlorambucil GSTP1 protein results in decreased susceptibility to Chlorambucil GSTP1 gene affects the susceptibility to Chlorambucil GSTP1 protein promotes the reaction [ABCC1 protein results in decreased susceptibility to Chlorambucil] |
CTD |
PMID:10900222 PMID:11071881 PMID:18511072 |
|
NCBI chr 1:219,291,679...219,294,147
Ensembl chr 1:219,291,679...219,294,147
|
|
G |
H2ax |
H2A.X variant histone |
increases phosphorylation |
ISO |
Chlorambucil analog results in increased phosphorylation of H2AX protein; Chlorambucil results in increased phosphorylation of H2AX protein |
CTD |
PMID:16861886 PMID:32482060 |
|
NCBI chr 8:48,665,652...48,666,981
Ensembl chr 8:48,665,652...48,666,981
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
ISO |
IL4 protein inhibits the reaction [[Theophylline co-treated with Chlorambucil] results in increased expression of MYC protein]; IL4 protein inhibits the reaction [[Theophylline co-treated with Chlorambucil] results in increased expression of TP53]; IL4 protein inhibits the reaction [Chlorambucil results in decreased expression of BCL2 protein] |
CTD |
PMID:8822937 |
|
NCBI chr10:38,963,979...38,969,531
Ensembl chr10:38,963,979...38,969,531
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
multiple interactions |
ISO |
[KEAP1 gene mutant form results in increased activity of NFE2L2] which results in decreased susceptibility to Chlorambucil; Buthionine Sulfoximine inhibits the reaction [[KEAP1 gene mutant form results in increased activity of NFE2L2] which results in decreased susceptibility to Chlorambucil] |
CTD |
PMID:19608619 |
|
NCBI chr 8:22,250,518...22,259,868
Ensembl chr 8:22,250,518...22,259,779
|
|
G |
Lif |
LIF, interleukin 6 family cytokine |
increases expression |
ISO |
Chlorambucil results in increased expression of LIF mRNA |
CTD |
PMID:26198647 |
|
NCBI chr14:84,482,652...84,500,574
Ensembl chr14:84,482,674...84,500,642
|
|
G |
LOC100912489 |
histone H4-like |
decreases expression |
ISO |
Chlorambucil analog results in decreased expression of H4C3 mRNA; Chlorambucil results in decreased expression of H4C3 mRNA; Chlorambucil results in decreased expression of H4C3 protein |
CTD |
PMID:15556009 PMID:16861886 |
|
NCBI chr 4:170,144,871...170,145,311
Ensembl chr 4:170,144,951...170,145,262
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
increases expression |
ISO |
Chlorambucil results in increased expression of MDM2 mRNA |
CTD |
PMID:17476690 |
|
NCBI chr 7:60,719,060...60,743,618
Ensembl chr 7:60,719,066...60,743,328
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions affects expression increases expression |
ISO |
[Theophylline co-treated with Chlorambucil] results in increased expression of MYC protein; IL4 protein inhibits the reaction [[Theophylline co-treated with Chlorambucil] results in increased expression of MYC protein] Chlorambucil affects the expression of MYC mRNA Chlorambucil results in increased expression of MYC protein |
CTD |
PMID:8822937 |
|
NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
|
|
G |
Myo5a |
myosin VA |
increases mutagenesis |
ISO |
Chlorambucil results in increased mutagenesis of MYO5A gene |
CTD |
PMID:10517996 |
|
NCBI chr 8:82,038,966...82,156,507
Ensembl chr 8:82,037,977...82,156,617
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
multiple interactions affects response to substance increases response to substance |
ISO |
[KEAP1 gene mutant form results in increased activity of NFE2L2] which results in decreased susceptibility to Chlorambucil; Buthionine Sulfoximine inhibits the reaction [[KEAP1 gene mutant form results in increased activity of NFE2L2] which results in decreased susceptibility to Chlorambucil] [NFE2L2 affects the susceptibility to sulforafan] which affects the susceptibility to Chlorambucil Buthionine Sulfoximine affects the reaction [[NFE2L2 affects the susceptibility to sulforafan] which affects the susceptibility to Chlorambucil]; Buthionine Sulfoximine inhibits the reaction [NFE2L2 protein promotes the reaction [sulforafan results in decreased susceptibility to Chlorambucil]]; NFE2L2 protein promotes the reaction [sulforafan results in decreased susceptibility to Chlorambucil] NFE2L2 gene mutant form results in increased susceptibility to Chlorambucil |
CTD |
PMID:19303893 PMID:19608619 PMID:20932822 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Piga |
phosphatidylinositol glycan anchor biosynthesis, class A |
increases mutagenesis multiple interactions |
EXP |
Chlorambucil results in increased mutagenesis of PIGA Chlorambucil results in increased mutagenesis of and results in decreased activity of PIGA protein |
CTD |
PMID:22923490 PMID:27931811 |
|
NCBI chr X:31,786,823...31,799,751
Ensembl chr X:31,786,194...31,799,560
|
|
G |
Rad51 |
RAD51 recombinase |
increases expression |
ISO |
Chlorambucil results in increased expression of RAD51 protein |
CTD |
PMID:10473103 |
|
NCBI chr 3:110,918,240...110,942,920
Ensembl chr 3:110,918,243...110,942,917
|
|
G |
RT1-Ha |
RT1 class II, locus Ha |
affects expression |
ISO |
Chlorambucil affects the expression of HLA-DPA1 mRNA |
CTD |
PMID:25811541 |
|
NCBI chr20:3,875,478...3,885,140
Ensembl chr20:3,875,706...3,881,461
|
|
G |
Sfn |
stratifin |
increases expression |
ISO |
Chlorambucil results in increased expression of SFN mRNA |
CTD |
PMID:18092340 |
|
NCBI chr 5:151,823,422...151,824,937
Ensembl chr 5:151,823,887...151,824,633
|
|
G |
Tnfrsf10b |
TNF receptor superfamily member 10b |
affects expression |
ISO |
Chlorambucil affects the expression of TNFRSF10A mRNA |
CTD |
PMID:14614459 |
|
NCBI chr15:51,433,853...51,464,215
|
|
G |
Tp53 |
tumor protein p53 |
increases expression multiple interactions |
ISO |
Chlorambucil results in increased expression of TP53; Chlorambucil results in increased expression of TP53 protein [Theophylline co-treated with Chlorambucil] results in increased expression of TP53; IL4 protein inhibits the reaction [[Theophylline co-treated with Chlorambucil] results in increased expression of TP53] |
CTD |
PMID:8822937 PMID:18092340 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
decreases activity |
EXP |
Chlorambucil results in decreased activity of TXNRD1 protein |
CTD |
PMID:16085187 |
|
NCBI chr 7:26,946,124...26,984,400
Ensembl chr 7:26,946,125...26,984,400
|
|
G |
Tyrp1 |
tyrosinase-related protein 1 |
increases mutagenesis |
ISO |
Chlorambucil results in increased mutagenesis of TYRP1 gene |
CTD |
PMID:10517996 |
|
NCBI chr 5:98,387,291...98,406,083
Ensembl chr 5:98,387,291...98,406,083
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions decreases expression increases expression |
ISO EXP |
[Cyclophosphamide results in increased activity of NR1I2 protein] which results in increased expression of ABCB1 mRNA; ABCB1 protein affects the susceptibility to [Cyclophosphamide co-treated with Methotrexate co-treated with Fluorouracil]; ABCB1 protein affects the susceptibility to [Fluorouracil co-treated with Epirubicin co-treated with Cyclophosphamide]; NR1I2 protein promotes the reaction [Cyclophosphamide results in increased expression of ABCB1 protein] Cyclophosphamide results in decreased expression of ABCB1 mRNA; Cyclophosphamide results in decreased expression of ABCB1A mRNA |
CTD |
PMID:12576456 PMID:20041327 PMID:20623750 PMID:30563925 |
|
NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
multiple interactions decreases response to substance |
ISO |
ABCC1 protein affects the susceptibility to [Fluorouracil co-treated with Epirubicin co-treated with Cyclophosphamide] ABCC1 protein results in decreased susceptibility to Cyclophosphamide |
CTD |
PMID:11778547 PMID:12576456 |
|
NCBI chr10:549,537...672,235
Ensembl chr10:549,883...672,196
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions |
ISO |
ABCG2 protein affects the susceptibility to [Fluorouracil co-treated with Epirubicin co-treated with Cyclophosphamide] |
CTD |
PMID:12576456 |
|
NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621
|
|
G |
Abhd3 |
abhydrolase domain containing 3, phospholipase |
increases expression |
ISO |
Cyclophosphamide results in increased expression of ABHD3 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr18:1,892,413...1,946,840
Ensembl chr18:1,892,413...1,946,840
|
|
G |
Abi2 |
abl-interactor 2 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of ABI2 mRNA |
CTD |
PMID:27466211 |
|
NCBI chr 9:67,234,612...67,284,504
Ensembl chr 9:67,234,303...67,282,600
|
|
G |
Ace |
angiotensin I converting enzyme |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of ACE mRNA |
CTD |
PMID:27281708 |
|
NCBI chr10:94,170,766...94,213,831
Ensembl chr10:94,170,766...94,187,822
|
|
G |
Ackr3 |
atypical chemokine receptor 3 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of ACKR3 mRNA |
CTD |
PMID:20032115 |
|
NCBI chr 9:97,355,881...97,367,455
Ensembl chr 9:97,355,924...97,367,445
|
|
G |
Acod1 |
aconitate decarboxylase 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of ACOD1 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr15:93,612,968...93,622,322
Ensembl chr15:93,612,971...93,622,358
|
|
G |
Actb |
actin, beta |
decreases expression affects expression |
ISO EXP |
Cyclophosphamide results in decreased expression of ACTB mRNA Cyclophosphamide affects the expression of ACTB mRNA |
CTD |
PMID:10859244 PMID:12167460 |
|
NCBI chr12:13,715,843...13,718,813
Ensembl chr12:13,715,843...13,718,841
|
|
G |
Adam24 |
a disintegrin and metallopeptidase domain 24 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of ADAM24 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr16:54,625,789...54,631,824
Ensembl chr16:54,625,847...54,628,458
|
|
G |
Adamts9 |
ADAM metallopeptidase with thrombospondin type 1 motif, 9 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of ADAMTS9 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 4:124,660,254...124,860,997
Ensembl chr 4:124,660,262...124,858,250
|
|
G |
Adcyap1 |
adenylate cyclase activating polypeptide 1 |
affects expression increases expression |
EXP |
Cyclophosphamide affects the expression of ADCYAP1 mRNA Cyclophosphamide results in increased expression of ADCYAP1 protein |
CTD |
PMID:9776515 PMID:10754506 PMID:18563302 |
|
NCBI chr 9:121,705,897...121,725,736
Ensembl chr 9:121,706,979...121,725,716
|
|
G |
Adcyap1r1 |
ADCYAP receptor type I |
affects expression |
EXP |
Cyclophosphamide affects the expression of ADCYAP1R1 mRNA |
CTD |
PMID:18563302 |
|
NCBI chr 4:85,662,809...85,711,696
Ensembl chr 4:85,662,892...85,711,696
|
|
G |
Adm |
adrenomedullin |
affects response to substance |
ISO |
ADM protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr 1:175,443,189...175,447,260
Ensembl chr 1:175,445,088...175,447,259
|
|
G |
Afp |
alpha-fetoprotein |
affects expression |
ISO |
Cyclophosphamide affects the expression of AFP protein |
CTD |
PMID:6177358 |
|
NCBI chr14:19,141,755...19,159,919
Ensembl chr14:19,141,755...19,159,923
|
|
G |
Agl |
amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase |
affects response to substance |
ISO |
AGL protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr 2:219,788,234...219,843,189
Ensembl chr 2:219,788,234...219,842,986
|
|
G |
Akap2 |
A-kinase anchoring protein 2 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of PALM2AKAP2 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 5:74,874,245...74,985,789
Ensembl chr 5:74,874,306...74,982,401
|
|
G |
Akap8 |
A-kinase anchoring protein 8 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of AKAP8 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 7:14,323,298...14,339,953
Ensembl chr 7:14,324,104...14,351,918
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions decreases expression |
EXP |
Cyclophosphamide results in increased phosphorylation of and results in increased activity of AKT1 protein; NGF protein affects the reaction [Cyclophosphamide results in increased phosphorylation of and results in increased activity of AKT1 protein]; Plant Extracts inhibits the reaction [Cyclophosphamide results in decreased expression of AKT1 protein] |
CTD |
PMID:19996110 PMID:25446862 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Alad |
aminolevulinate dehydratase |
multiple interactions |
ISO |
[Cyclophosphamide co-treated with Carmustine co-treated with Etoposide] results in decreased activity of ALAD protein |
CTD |
PMID:19162187 |
|
NCBI chr 5:78,368,867...78,379,206
Ensembl chr 5:78,368,867...78,379,346
|
|
G |
Alcam |
activated leukocyte cell adhesion molecule |
increases expression |
ISO |
Cyclophosphamide results in increased expression of ALCAM mRNA |
CTD |
PMID:21041162 |
|
NCBI chr11:50,780,735...50,985,083
Ensembl chr11:50,781,127...50,985,083
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
affects response to substance increases expression decreases response to substance |
ISO |
ALDH1A1 protein affects the susceptibility to Cyclophosphamide Cyclophosphamide results in increased expression of ALDH1A1 mRNA ALDH1A1 protein results in decreased susceptibility to Cyclophosphamide |
CTD |
PMID:12513786 PMID:17403535 PMID:18854779 |
|
NCBI chr 1:238,222,689...238,264,381
Ensembl chr 1:238,222,521...238,264,330
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2 family member |
increases expression |
ISO |
Cyclophosphamide results in increased expression of ALDH2 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr12:40,466,418...40,498,813
Ensembl chr12:40,466,495...40,498,752
|
|
G |
Aldh3a1 |
aldehyde dehydrogenase 3 family, member A1 |
affects response to substance |
ISO |
ALDH3A1 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:18854779 |
|
NCBI chr10:47,490,168...47,499,855
Ensembl chr10:47,490,153...47,499,876
|
|
G |
Alox5ap |
arachidonate 5-lipoxygenase activating protein |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of ALOX5AP mRNA |
CTD |
PMID:17403535 |
|
NCBI chr12:6,854,930...6,879,112
Ensembl chr12:6,854,920...6,879,154
|
|
G |
Alyref |
Aly/REF export factor |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of ALYREF mRNA |
CTD |
PMID:21041162 |
|
NCBI chr10:109,768,593...109,774,639
Ensembl chr10:109,770,876...109,774,639
|
|
G |
Amfr |
autocrine motility factor receptor |
multiple interactions |
ISO |
AMFR mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr19:11,473,538...11,509,500
Ensembl chr19:11,473,541...11,508,102
|
|
G |
Angpt1 |
angiopoietin 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of ANGPT1 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 7:81,338,327...81,592,459
Ensembl chr 7:81,342,280...81,592,206
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of APAF1 mRNA |
CTD |
PMID:29445054 |
|
NCBI chr 7:31,699,309...31,784,192
Ensembl chr 7:31,699,885...31,784,192
|
|
G |
Apex1 |
apurinic/apyrimidinic endodeoxyribonuclease 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of APEX1 mRNA |
CTD |
PMID:11599041 |
|
NCBI chr15:27,849,943...27,852,083
Ensembl chr15:27,849,979...27,852,082
|
|
G |
Apob |
apolipoprotein B |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of APOB mRNA |
CTD |
PMID:18246545 |
|
NCBI chr 6:33,176,826...33,216,381
Ensembl chr 6:33,176,778...33,224,997
|
|
G |
Apoe |
apolipoprotein E |
decreases expression increases expression |
ISO |
Cyclophosphamide results in decreased expression of APOE mRNA Cyclophosphamide results in increased expression of APOE mRNA |
CTD |
PMID:15331540 PMID:21041162 |
|
NCBI chr 1:80,612,894...80,616,820
Ensembl chr 1:80,612,895...80,617,057
|
|
G |
Arg1 |
arginase 1 |
increases expression decreases expression affects expression |
ISO EXP |
Cyclophosphamide results in increased expression of ARG1 mRNA Cyclophosphamide results in decreased expression of ARG1 mRNA Cyclophosphamide affects the expression of ARG1 mRNA |
CTD |
PMID:18246545 PMID:21068404 |
|
NCBI chr 1:21,525,421...21,537,872
Ensembl chr 1:21,525,421...21,537,863
|
|
G |
Arhgdib |
Rho GDP dissociation inhibitor beta |
increases expression |
ISO |
Cyclophosphamide results in increased expression of ARHGDIB mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 4:170,913,920...170,932,789
Ensembl chr 4:170,913,923...170,932,618
|
|
G |
Arhgef26 |
Rho guanine nucleotide exchange factor 26 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of ARHGEF26 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 2:27,107,263...27,236,336
Ensembl chr 2:27,107,318...27,236,672
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of ASNS mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 4:33,742,876...33,761,106
Ensembl chr 4:33,743,364...33,761,163
|
|
G |
Atf2 |
activating transcription factor 2 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of ATF2 mRNA |
CTD |
PMID:11599041 |
|
NCBI chr 3:60,721,137...60,795,951
Ensembl chr 3:60,721,135...60,795,951
|
|
G |
Atf5 |
activating transcription factor 5 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of ATF5 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 1:100,807,821...100,812,410
Ensembl chr 1:100,808,241...100,810,522
|
|
G |
Atg3 |
autophagy related 3 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of ATG3 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr11:60,585,192...60,613,706
Ensembl chr11:60,585,171...60,613,718
|
|
G |
Atg5 |
autophagy related 5 |
decreases expression multiple interactions |
ISO |
Cyclophosphamide results in decreased expression of ATG5 protein Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of ATG5 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of ATG5 protein] |
CTD |
PMID:32151603 |
|
NCBI chr20:49,301,783...49,393,147
Ensembl chr20:49,318,308...49,393,140
|
|
G |
Atg7 |
autophagy related 7 |
decreases expression multiple interactions |
ISO |
Cyclophosphamide results in decreased expression of ATG7 protein Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of ATG7 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of ATG7 protein] |
CTD |
PMID:32151603 |
|
NCBI chr 4:146,570,113...146,777,093
Ensembl chr 4:146,598,413...146,777,124
|
|
G |
Aurkb |
aurora kinase B |
increases expression |
EXP |
Cyclophosphamide results in increased expression of AURKB mRNA |
CTD |
PMID:11599041 |
|
NCBI chr10:55,625,860...55,632,399
Ensembl chr10:55,626,741...55,634,991
|
|
G |
Axl |
Axl receptor tyrosine kinase |
increases expression |
ISO |
Cyclophosphamide results in increased expression of AXL mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 1:82,550,892...82,580,761
Ensembl chr 1:82,549,420...82,580,761
|
|
G |
B3galnt2 |
beta-1,3-N-acetylgalactosaminyltransferase 2 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of B3GALNT2 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr17:54,027,859...54,070,399
Ensembl chr17:54,027,859...54,070,399
|
|
G |
Bad |
BCL2-associated agonist of cell death |
increases expression multiple interactions |
EXP ISO |
Cyclophosphamide results in increased expression of BAD mRNA Cyclophosphamide results in increased expression of BAD protein Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in increased expression of BAD protein] |
CTD |
PMID:11599041 PMID:29753871 |
|
NCBI chr 1:222,198,516...222,207,459
Ensembl chr 1:222,198,534...222,207,453
|
|
G |
Bag1 |
BAG cochaperone 1 |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of BAG1 mRNA |
CTD |
PMID:16322899 |
|
NCBI chr 5:57,254,421...57,267,002
Ensembl chr 5:57,254,421...57,267,002
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
EXP ISO |
Cyclophosphamide results in increased expression of BAX mRNA; Cyclophosphamide results in increased expression of BAX protein Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in increased expression of BAX protein]; ganoderic acid A inhibits the reaction [Cyclophosphamide results in increased expression of BAX protein] Plant Extracts inhibits the reaction [Cyclophosphamide results in increased expression of BAX mRNA]; sacubitril-valsartan inhibits the reaction [Cyclophosphamide results in increased expression of BAX protein]; Valsartan inhibits the reaction [Cyclophosphamide results in increased expression of BAX protein] |
CTD |
PMID:25446862 PMID:29753871 PMID:30506662 PMID:32197949 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
increases expression multiple interactions |
EXP |
Cyclophosphamide results in increased expression of BBC3 mRNA sacubitril-valsartan inhibits the reaction [Cyclophosphamide results in increased expression of BBC3 mRNA]; Valsartan inhibits the reaction [Cyclophosphamide results in increased expression of BBC3 mRNA] |
CTD |
PMID:32197949 |
|
NCBI chr 1:78,261,491...78,267,802
|
|
G |
Bbs4 |
Bardet-Biedl syndrome 4 |
multiple interactions |
ISO |
BBS4 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr 8:64,115,005...64,154,432
Ensembl chr 8:64,121,392...64,154,396
|
|
G |
Bche |
butyrylcholinesterase |
multiple interactions decreases activity |
ISO |
[Melphalan co-treated with Thiotepa co-treated with Cyclophosphamide] results in decreased expression of BCHE protein Cyclophosphamide results in decreased activity of BCHE protein |
CTD |
PMID:4672170 PMID:4959505 |
|
NCBI chr 2:171,104,476...171,196,186
Ensembl chr 2:171,100,140...171,196,395
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression increases expression |
ISO EXP |
[Cladribine co-treated with Cyclophosphamide co-treated with Mitoxantrone] results in decreased expression of BCL2 protein; [Cladribine co-treated with Cyclophosphamide] results in decreased expression of BCL2 protein; [Doxorubicin co-treated with Cyclophosphamide] affects the expression of BCL2 mRNA; [Doxorubicin co-treated with Dexamethasone co-treated with Vincristine co-treated with Cytarabine co-treated with Mercaptopurine co-treated with Methotrexate co-treated with Cyclophosphamide co-treated with Enzymes and Coenzymes] results in increased expression of BCL2 protein; BCL2 protein inhibits the reaction [Cyclophosphamide results in increased activity of CASP3 protein]; BCL2 protein inhibits the reaction [Cyclophosphamide results in increased activity of CASP9 protein] Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of BCL2 protein]; ganoderic acid A inhibits the reaction [Cyclophosphamide results in decreased expression of BCL2 protein] Plant Extracts inhibits the reaction [Cyclophosphamide results in decreased expression of BCL2 mRNA]; sacubitril-valsartan inhibits the reaction [Cyclophosphamide results in decreased expression of BCL2 protein]; Valsartan inhibits the reaction [Cyclophosphamide results in decreased expression of BCL2 protein] Cyclophosphamide results in decreased expression of BCL2 mRNA; Cyclophosphamide results in decreased expression of BCL2 protein Cyclophosphamide results in increased expression of BCL2 mRNA |
CTD |
PMID:11723234 PMID:14503796 PMID:15582267 PMID:16322899 PMID:21182165 PMID:25446862 PMID:29753871 PMID:30506662 PMID:32197949 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of BCL2L1 mRNA |
CTD |
PMID:11599041 |
|
NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
|
|
G |
Bcl2l11 |
BCL2 like 11 |
increases expression multiple interactions |
EXP |
Cyclophosphamide results in increased expression of BCL2L11 mRNA sacubitril-valsartan inhibits the reaction [Cyclophosphamide results in increased expression of BCL2L11 mRNA]; Valsartan inhibits the reaction [Cyclophosphamide results in increased expression of BCL2L11 mRNA] |
CTD |
PMID:32197949 |
|
NCBI chr 3:120,726,906...120,764,192
Ensembl chr 3:120,726,906...120,764,192
|
|
G |
Bcl2l2 |
Bcl2-like 2 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of BCL2L2 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr15:33,543,774...33,549,165
Ensembl chr15:33,544,312...33,549,164
|
|
G |
Bcl6 |
BCL6, transcription repressor |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of BCL6 mRNA Cyclophosphamide metabolite results in decreased expression of BCL6 mRNA |
CTD |
PMID:21041162 PMID:24356939 |
|
NCBI chr11:80,255,790...80,279,075
Ensembl chr11:80,255,790...80,279,075
|
|
G |
Bdh1 |
3-hydroxybutyrate dehydrogenase 1 |
affects response to substance |
ISO |
BDH1 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr11:72,577,547...72,619,435
Ensembl chr11:72,578,533...72,614,176
|
|
G |
Bdkrb1 |
bradykinin receptor B1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of BDKRB1 mRNA |
CTD |
PMID:10498854 PMID:15576455 |
|
NCBI chr 6:129,437,423...129,441,553
Ensembl chr 6:129,438,158...129,440,574
|
|
G |
Bdkrb2 |
bradykinin receptor B2 |
affects expression |
EXP |
Cyclophosphamide affects the expression of BDKRB2 mRNA |
CTD |
PMID:15576455 |
|
NCBI chr 6:129,399,468...129,429,676
Ensembl chr 6:129,399,468...129,429,676
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
increases expression |
EXP |
Cyclophosphamide results in increased expression of BDNF mRNA |
CTD |
PMID:10683293 |
|
NCBI chr 3:100,768,637...100,819,216
Ensembl chr 3:100,768,637...100,819,210
|
|
G |
Becn1 |
beclin 1 |
multiple interactions decreases expression |
ISO |
BECN1 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of BECN1 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of BECN1 protein] |
CTD |
PMID:16896004 PMID:32151603 |
|
NCBI chr10:89,209,944...89,225,297
Ensembl chr10:89,209,940...89,225,297
|
|
G |
Bik |
BCL2-interacting killer |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of BIK mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 7:124,390,924...124,410,449
Ensembl chr 7:124,391,432...124,410,447
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of BIRC3 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 8:6,048,590...6,076,828
Ensembl chr 8:6,048,969...6,076,598
|
|
G |
Blvrb |
biliverdin reductase B |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of BLVRB protein |
CTD |
PMID:9006340 |
|
NCBI chr 1:84,256,063...84,273,726
Ensembl chr 1:84,256,159...84,274,075
|
|
G |
Bpi |
bactericidal/permeability-increasing protein |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of BPI mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 3:154,741,627...154,768,584
Ensembl chr 3:154,741,631...154,768,640
|
|
G |
Brpf1 |
bromodomain and PHD finger containing, 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of BRPF1 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 4:145,264,445...145,280,943
Ensembl chr 4:145,264,462...145,280,857
|
|
G |
Bscl2 |
BSCL2 lipid droplet biogenesis associated, seipin |
increases expression |
ISO |
Cyclophosphamide results in increased expression of BSCL2 mRNA |
CTD |
PMID:22003191 |
|
NCBI chr 1:225,035,956...225,046,137
Ensembl chr 1:225,037,737...225,046,040
|
|
G |
Bsg |
basigin (Ok blood group) |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of BSG mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 7:12,875,536...12,882,753
Ensembl chr 7:12,875,537...12,882,753
|
|
G |
Btg1 |
BTG anti-proliferation factor 1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of BTG1 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 7:37,812,831...37,815,088
Ensembl chr 7:37,812,831...37,815,088
|
|
G |
Btg2 |
BTG anti-proliferation factor 2 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of BTG2 mRNA |
CTD |
PMID:29445054 |
|
NCBI chr13:50,913,185...50,916,944
Ensembl chr13:50,913,180...50,916,982
|
|
G |
Btg3 |
BTG anti-proliferation factor 3 |
multiple interactions |
ISO |
BTG3 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr11:16,873,642...16,889,100
Ensembl chr11:16,873,646...16,889,201
|
|
G |
Bub3 |
BUB3 mitotic checkpoint protein |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of BUB3 mRNA |
CTD |
PMID:16322899 |
|
NCBI chr 1:203,526,853...203,537,459
Ensembl chr 1:203,524,426...203,557,337
|
|
G |
C1qa |
complement C1q A chain |
increases expression |
ISO |
Cyclophosphamide results in increased expression of C1QA mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 5:155,261,254...155,264,101
Ensembl chr 5:155,261,250...155,264,143
|
|
G |
C3 |
complement C3 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of C3 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 9:9,721,137...9,747,084
Ensembl chr 9:9,721,105...9,747,167
|
|
G |
Ca12 |
carbonic anhydrase 12 |
multiple interactions |
ISO |
CA12 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr 8:72,405,770...72,461,425
Ensembl chr 8:72,405,748...72,460,240
|
|
G |
Cabp1 |
calcium binding protein 1 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of CABP1 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr12:47,185,449...47,209,785
Ensembl chr12:47,179,664...47,209,784
|
|
G |
Cabp2 |
calcium binding protein 2 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of CABP2 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 1:219,329,186...219,335,046
Ensembl chr 1:219,329,574...219,335,043
|
|
G |
Cacna1h |
calcium voltage-gated channel subunit alpha1 H |
increases expression multiple interactions |
ISO |
Cyclophosphamide results in increased expression of CACNA1H protein 3-cyanoalanine inhibits the reaction [[N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine co-treated with Cyclophosphamide] results in increased expression of CACNA1H protein]; [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine co-treated with Cyclophosphamide] results in increased expression of CACNA1H protein |
CTD |
PMID:29129814 |
|
NCBI chr10:14,730,932...14,789,201
Ensembl chr10:14,730,941...14,788,617
|
|
G |
Calr |
calreticulin |
increases expression decreases expression |
EXP |
Cyclophosphamide results in increased expression of CALR mRNA Cyclophosphamide results in decreased expression of CALR mRNA |
CTD |
PMID:11599041 PMID:11906922 PMID:18246545 |
|
NCBI chr19:25,956,771...25,961,666
Ensembl chr19:25,956,771...25,961,666
|
|
G |
Canx |
calnexin |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of CANX mRNA |
CTD |
PMID:11906922 |
|
NCBI chr10:35,800,942...35,833,939
Ensembl chr10:35,800,942...35,833,861
|
|
G |
Capn2 |
calpain 2 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CAPN2 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr13:100,878,649...100,928,811
Ensembl chr13:100,878,650...100,928,811
|
|
G |
Car2 |
carbonic anhydrase 2 |
decreases expression increases expression |
ISO |
Cyclophosphamide results in decreased expression of CA2 mRNA Cyclophosphamide results in increased expression of CAR2 mRNA |
CTD |
PMID:15331540 PMID:17403535 |
|
NCBI chr 2:88,097,740...88,112,868
Ensembl chr 2:88,097,720...88,113,029
|
|
G |
Car7 |
carbonic anhydrase 7 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of CAR7 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr19:636,545...645,935
Ensembl chr19:636,545...645,937
|
|
G |
Cars |
cysteinyl-tRNA synthetase |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of CARS1 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 1:216,759,367...216,801,652
Ensembl chr 1:216,759,366...216,801,656
|
|
G |
Casp1 |
caspase 1 |
decreases expression increases expression |
ISO |
Cyclophosphamide results in decreased expression of CASP1 mRNA Cyclophosphamide results in increased expression of CASP1 mRNA |
CTD |
PMID:17403535 PMID:21041162 |
|
NCBI chr 8:2,605,743...2,614,637
Ensembl chr 8:2,604,962...2,614,631
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity increases expression decreases response to substance |
ISO EXP |
[Bortezomib co-treated with oblimersen co-treated with Cyclophosphamide] results in increased activity of CASP3 protein; BCL2 protein inhibits the reaction [Cyclophosphamide results in increased activity of CASP3 protein]; Cyclophosphamide results in increased cleavage of and results in increased activity of CASP3 protein sacubitril-valsartan inhibits the reaction [Cyclophosphamide results in increased activity of CASP3 protein]; Valsartan inhibits the reaction [Cyclophosphamide results in increased activity of CASP3 protein] Cyclophosphamide results in increased expression of CASP3 protein ganoderic acid A inhibits the reaction [Cyclophosphamide results in increased expression of CASP3 protein] Cyclophosphamide results in increased expression of CASP3 mRNA CASP3 protein alternative form results in decreased susceptibility to Cyclophosphamide |
CTD |
PMID:11723234 PMID:14503796 PMID:16675587 PMID:17020986 PMID:17898787 PMID:30506662 PMID:32197949 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp4 |
caspase 4 |
increases cleavage multiple interactions |
EXP |
Cyclophosphamide results in increased cleavage of CASP4 protein sacubitril-valsartan inhibits the reaction [Cyclophosphamide results in increased cleavage of CASP4 protein]; Valsartan inhibits the reaction [Cyclophosphamide results in increased cleavage of CASP4 protein] |
CTD |
PMID:32197949 |
|
NCBI chr 8:2,616,391...2,651,682
Ensembl chr 8:2,635,851...2,651,652
|
|
G |
Casp8 |
caspase 8 |
multiple interactions increases response to substance |
ISO |
[Methotrexate results in increased expression of CASP8 protein] which results in increased susceptibility to Cyclophosphamide metabolite; Cyclophosphamide metabolite results in increased expression of and results in increased cleavage of CASP8 protein; Cyclophosphamide results in increased cleavage of and results in increased activity of CASP8 protein CASP8 protein results in increased susceptibility to Cyclophosphamide metabolite |
CTD |
PMID:17898787 PMID:22010212 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases expression increases activity |
ISO EXP |
BCL2 protein inhibits the reaction [Cyclophosphamide results in increased activity of CASP9 protein]; Cyclophosphamide results in increased cleavage of and results in increased activity of CASP9 protein ganoderic acid A inhibits the reaction [Cyclophosphamide results in increased expression of CASP9 protein] |
CTD |
PMID:11723234 PMID:17898787 PMID:30506662 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Cat |
catalase |
decreases expression decreases activity affects activity multiple interactions |
EXP ISO |
Cyclophosphamide results in decreased expression of CAT protein Cyclophosphamide results in decreased activity of CAT protein Cyclophosphamide results in decreased expression of CAT mRNA; Cyclophosphamide results in decreased expression of CAT protein Cyclophosphamide affects the activity of CAT protein Buthionine Sulfoximine promotes the reaction [Cyclophosphamide results in decreased activity of CAT protein]; cinnamic acid inhibits the reaction [Cyclophosphamide affects the activity of CAT protein]; Cyclophosphamide promotes the reaction [NFE2L2 gene mutant form results in decreased expression of CAT protein]; Eicosapentaenoic Acid inhibits the reaction [Cyclophosphamide affects the activity of CAT protein]; Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased activity of CAT protein]; NFE2L2 gene mutant form promotes the reaction [Cyclophosphamide results in decreased expression of CAT protein]; Plant Extracts inhibits the reaction [Buthionine Sulfoximine promotes the reaction [Cyclophosphamide results in decreased activity of CAT protein]]; Plant Extracts inhibits the reaction [Cyclophosphamide results in decreased activity of CAT protein]; Plant Extracts inhibits the reaction [Cyclophosphamide results in decreased expression of CAT mRNA] mangiferin inhibits the reaction [Cyclophosphamide results in decreased activity of CAT protein]; Pentoxifylline inhibits the reaction [Cyclophosphamide results in decreased activity of CAT protein]; pimagedine inhibits the reaction [Cyclophosphamide results in decreased expression of CAT protein]; Rutin inhibits the reaction [Cyclophosphamide results in decreased activity of CAT protein]; thymoquinone inhibits the reaction [Cyclophosphamide results in decreased activity of CAT protein] |
CTD |
PMID:16076520 PMID:19107871 PMID:20052769 PMID:20957680 PMID:21772021 PMID:22285266 PMID:23542512 PMID:23695977 PMID:25753322 PMID:27633142 PMID:29753871 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Ccin |
calicin |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CCIN protein |
CTD |
PMID:17475930 |
|
NCBI chr 5:59,452,348...59,454,235
Ensembl chr 5:59,452,348...59,454,233
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression increases expression |
EXP ISO |
Cyclophosphamide results in decreased expression of CCL2 protein Cyclophosphamide results in increased expression of CCL2 mRNA |
CTD |
PMID:18848347 PMID:21068404 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ccl25 |
C-C motif chemokine ligand 25 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CCL25 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr12:2,429,492...2,438,928
Ensembl chr12:2,429,509...2,438,817
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CCL3 protein |
CTD |
PMID:21880982 |
|
NCBI chr10:70,869,516...70,871,066
Ensembl chr10:70,869,513...70,871,066
|
|
G |
Ccl7 |
C-C motif chemokine ligand 7 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CCL7 mRNA |
CTD |
PMID:15331540 PMID:21041162 |
|
NCBI chr10:69,423,083...69,424,933
Ensembl chr10:69,423,086...69,424,979
|
|
G |
Ccna2 |
cyclin A2 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CCNA2 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 2:123,274,727...123,282,266
Ensembl chr 2:123,275,881...123,282,214
|
|
G |
Ccnd2 |
cyclin D2 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CCND2 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 4:159,674,885...159,697,207
Ensembl chr 4:159,674,885...159,697,207
|
|
G |
Ccnd3 |
cyclin D3 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CCND3 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 9:15,404,816...15,410,905
Ensembl chr 9:15,404,822...15,410,943
|
|
G |
Ccr5 |
C-C motif chemokine receptor 5 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CCR5 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 8:133,192,398...133,215,599
Ensembl chr 8:133,197,032...133,215,614
|
|
G |
Ccr8 |
C-C motif chemokine receptor 8 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CCR8 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 8:128,779,552...128,782,531
Ensembl chr 8:128,781,395...128,782,456
|
|
G |
Ccr9 |
C-C motif chemokine receptor 9 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CCR9 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 8:132,827,325...132,842,130
Ensembl chr 8:132,828,091...132,842,130
|
|
G |
Cct3 |
chaperonin containing TCP1 subunit 3 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of CCT3 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 2:187,669,051...187,693,610
Ensembl chr 2:187,668,796...187,693,610
|
|
G |
Cct5 |
chaperonin containing TCP1 subunit 5 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of CCT5 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 2:84,667,578...84,678,730
Ensembl chr 2:84,667,633...84,678,790
|
|
G |
Cct7 |
chaperonin containing TCP1 subunit 7 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of CCT7 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 4:117,235,023...117,252,265
Ensembl chr 4:117,235,023...117,252,265
|
|
G |
Cd14 |
CD14 molecule |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CD14 mRNA |
CTD |
PMID:15331540 PMID:21041162 |
|
NCBI chr18:29,560,341...29,562,290
Ensembl chr18:29,560,365...29,562,153
|
|
G |
Cd151 |
CD151 molecule (Raph blood group) |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CD151 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 1:214,446,659...214,450,668
Ensembl chr 1:214,009,784...214,013,765 Ensembl chr 1:214,009,784...214,013,765
|
|
G |
Cd2 |
Cd2 molecule |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CD2 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 2:203,666,706...203,680,073
Ensembl chr 2:203,666,637...203,680,083
|
|
G |
Cd27 |
CD27 molecule |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CD27 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 4:157,744,881...157,751,609
Ensembl chr 4:157,744,882...157,750,088
|
|
G |
Cd28 |
Cd28 molecule |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CD28 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 9:67,546,408...67,573,858
Ensembl chr 9:67,546,408...67,571,871
|
|
G |
Cd38 |
CD38 molecule |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CD38 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr14:71,714,768...71,754,990
Ensembl chr14:71,715,269...71,754,672
|
|
G |
Cd3d |
CD3d molecule |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CD3D mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 8:49,282,502...49,287,095
Ensembl chr 8:49,282,460...49,287,110
|
|
G |
Cd3e |
CD3e molecule |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CD3E mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 8:49,297,604...49,309,370
Ensembl chr 8:49,297,608...49,308,806
|
|
G |
Cd3g |
CD3g molecule |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CD3G mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 8:49,274,553...49,280,943
Ensembl chr 8:49,274,960...49,280,901
|
|
G |
Cd4 |
Cd4 molecule |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CD4 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 4:157,381,862...157,408,357
Ensembl chr 4:157,383,052...157,408,176
|
|
G |
Cd40 |
CD40 molecule |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CD40 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 3:161,519,789...161,534,943
Ensembl chr 3:161,519,743...161,534,704
|
|
G |
Cd5 |
Cd5 molecule |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CD5 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 1:226,770,912...226,791,861
Ensembl chr 1:226,770,744...226,791,879
|
|
G |
Cd6 |
Cd6 molecule |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CD6 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 1:226,848,399...226,887,259
Ensembl chr 1:226,848,403...226,887,156
|
|
G |
Cd69 |
Cd69 molecule |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CD69 mRNA Cyclophosphamide metabolite results in decreased expression of CD69 mRNA |
CTD |
PMID:21041162 PMID:24356939 |
|
NCBI chr 4:163,041,147...163,049,065
Ensembl chr 4:163,041,141...163,049,084
|
|
G |
Cd74 |
CD74 molecule |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CD74 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr18:56,071,420...56,080,851
Ensembl chr18:56,071,478...56,080,849
|
|
G |
Cd79b |
CD79b molecule |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CD79B mRNA |
CTD |
PMID:15331540 |
|
NCBI chr10:94,497,445...94,500,591
Ensembl chr10:94,497,448...94,500,591
|
|
G |
Cd83 |
CD83 molecule |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CD83 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr17:24,416,651...24,435,790
Ensembl chr17:24,416,651...24,435,790
|
|
G |
Cd84 |
CD84 molecule |
increases expression |
ISO |
Cyclophosphamide metabolite results in increased expression of CD84 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr13:90,241,369...90,283,625
Ensembl chr13:90,244,681...90,277,865
|
|
G |
Cd8a |
CD8a molecule |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CD8A mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 4:99,217,640...99,243,352
Ensembl chr 4:99,239,115...99,243,351
|
|
G |
Cd8b |
CD8b molecule |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CD8B1 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 4:99,185,960...99,201,887
Ensembl chr 4:99,185,885...99,202,023
|
|
G |
Cdc20 |
cell division cycle 20 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of CDC20 mRNA |
CTD |
PMID:11599041 |
|
NCBI chr 5:137,260,728...137,264,931
Ensembl chr 5:137,260,739...137,265,015
|
|
G |
Cdh1 |
cadherin 1 |
affects expression |
EXP |
Cyclophosphamide affects the expression of CDH1 mRNA |
CTD |
PMID:10859244 |
|
NCBI chr19:38,768,467...38,838,395
Ensembl chr19:38,768,467...38,838,395
|
|
G |
Cdh2 |
cadherin 2 |
affects expression |
EXP |
Cyclophosphamide affects the expression of CDH2 mRNA |
CTD |
PMID:10859244 |
|
NCBI chr18:8,146,971...8,366,037
Ensembl chr18:8,146,971...8,360,684
|
|
G |
Cdh3 |
cadherin 3 |
affects expression |
EXP |
Cyclophosphamide affects the expression of CDH3 mRNA |
CTD |
PMID:10859244 |
|
NCBI chr19:38,668,957...38,719,801
Ensembl chr19:38,669,230...38,719,677
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CDK2 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 7:3,124,953...3,132,533
Ensembl chr 7:3,124,954...3,132,457
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CDKN1A mRNA |
CTD |
PMID:15331540 PMID:21527772 PMID:29445054 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of CDKN1B mRNA |
CTD |
PMID:16322899 |
|
NCBI chr 4:168,689,043...168,694,159
Ensembl chr 4:168,689,163...168,693,964
|
|
G |
Cdkn1c |
cyclin-dependent kinase inhibitor 1C |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CDKN1C mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 1:216,661,067...216,663,791
Ensembl chr 1:216,661,080...216,663,721
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of CEBPB mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 3:164,424,502...164,425,933
Ensembl chr 3:164,424,515...164,425,910
|
|
G |
Cel |
carboxyl ester lipase |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CEL mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 3:7,134,021...7,141,522
Ensembl chr 3:7,134,021...7,141,522
|
|
G |
Cfb |
complement factor B |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CFB mRNA |
CTD |
PMID:21041162 |
|
NCBI chr20:4,536,206...4,542,073
Ensembl chr20:4,536,203...4,561,066 Ensembl chr20:4,536,203...4,561,066
|
|
G |
Cfi |
complement factor I |
affects response to substance |
ISO |
CFI protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr 2:235,264,149...235,305,779
Ensembl chr 2:235,264,219...235,305,781
|
|
G |
Chac1 |
ChaC glutathione-specific gamma-glutamylcyclotransferase 1 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of CHAC1 mRNA; Cyclophosphamide results in decreased expression of CHAC1 mRNA |
CTD |
PMID:23824090 PMID:24356939 |
|
NCBI chr 3:111,160,205...111,163,425
Ensembl chr 3:111,160,205...111,163,425
|
|
G |
Champ1 |
chromosome alignment maintaining phosphoprotein 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of CHAMP1 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr16:80,839,373...80,850,340
Ensembl chr16:80,839,374...80,850,340
|
|
G |
Chd5 |
chromodomain helicase DNA binding protein 5 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of CHD5 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 5:169,519,212...169,572,059
Ensembl chr 5:169,519,212...169,567,107
|
|
G |
Chga |
chromogranin A |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CHGA mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 6:126,434,226...126,445,569
Ensembl chr 6:126,434,226...126,445,568
|
|
G |
Chrm5 |
cholinergic receptor, muscarinic 5 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of CHRM5 protein |
CTD |
PMID:16125470 |
|
NCBI chr 3:103,966,451...104,018,815
Ensembl chr 3:103,966,451...104,018,861
|
|
G |
Cited2 |
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 |
affects expression decreases expression |
EXP |
Cyclophosphamide affects the expression of CITED2 mRNA Cyclophosphamide results in decreased expression of CITED2 mRNA |
CTD |
PMID:18246545 |
|
NCBI chr 1:12,823,363...12,825,806
Ensembl chr 1:12,823,363...12,825,786
|
|
G |
Cldn1 |
claudin 1 |
multiple interactions decreases expression |
ISO |
Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of CLDN1 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of CLDN1 protein] |
CTD |
PMID:32151603 |
|
NCBI chr11:77,815,216...77,830,373
Ensembl chr11:77,815,181...77,830,416
|
|
G |
Cldn4 |
claudin 4 |
multiple interactions decreases expression |
EXP |
Anthocyanins inhibits the reaction [Cyclophosphamide results in decreased expression of CLDN4 protein]; Plant Extracts inhibits the reaction [Cyclophosphamide results in decreased expression of CLDN4 protein] |
CTD |
PMID:25451569 |
|
NCBI chr12:24,761,210...24,763,008
Ensembl chr12:24,761,210...24,763,005
|
|
G |
Clic4 |
chloride intracellular channel 4 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CLIC4 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 5:153,568,937...153,625,669
Ensembl chr 5:153,568,745...153,625,869
|
|
G |
Clip1 |
CAP-GLY domain containing linker protein 1 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of CLIP1 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr12:38,345,203...38,452,650
Ensembl chr12:38,345,456...38,452,652
|
|
G |
Coch |
cochlin |
affects response to substance |
ISO |
COCH protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr 6:72,359,702...72,373,710
Ensembl chr 6:72,359,791...72,373,695
|
|
G |
Comt |
catechol-O-methyltransferase |
increases expression |
ISO |
Cyclophosphamide results in increased expression of COMT mRNA |
CTD |
PMID:21041162 |
|
NCBI chr11:86,715,981...86,735,630
Ensembl chr11:86,715,981...86,735,622
|
|
G |
Cox7a2 |
cytochrome c oxidase subunit 7A2 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of COX7A2 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 8:87,209,529...87,213,627
Ensembl chr 8:87,209,530...87,213,627
|
|
G |
Crabp2 |
cellular retinoic acid binding protein 2 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CRABP2 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 2:187,322,416...187,326,794
Ensembl chr 2:184,882,969...184,883,505
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CREB1 protein modified form |
CTD |
PMID:18299998 |
|
NCBI chr 9:71,229,753...71,298,994
Ensembl chr 9:71,230,108...71,293,435
|
|
G |
Crem |
cAMP responsive element modulator |
decreases expression multiple interactions |
EXP |
Cyclophosphamide results in decreased expression of CREM mRNA; Cyclophosphamide results in decreased expression of CREM protein Drugs, Chinese Herbal inhibits the reaction [Cyclophosphamide results in decreased expression of CREM mRNA]; Drugs, Chinese Herbal inhibits the reaction [Cyclophosphamide results in decreased expression of CREM protein] |
CTD |
PMID:17624719 |
|
NCBI chr17:57,021,704...57,090,888
Ensembl chr17:57,031,766...57,090,888
|
|
G |
Crh |
corticotropin releasing hormone |
increases expression |
EXP ISO |
Cyclophosphamide results in increased expression of CRH mRNA; Cyclophosphamide results in increased expression of CRH protein |
CTD |
PMID:15276878 PMID:16614059 PMID:17335920 |
|
NCBI chr 2:104,459,999...104,461,863
Ensembl chr 2:104,459,999...104,461,863
|
|
G |
Crhr2 |
corticotropin releasing hormone receptor 2 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of CRHR2 protein |
CTD |
PMID:16614059 |
|
NCBI chr 4:85,286,371...85,329,374
Ensembl chr 4:85,286,372...85,329,362
|
|
G |
Csf1 |
colony stimulating factor 1 |
multiple interactions |
ISO |
[Cyclophosphamide co-treated with Sizofiran] results in increased expression of CSF1 mRNA |
CTD |
PMID:10052129 |
|
NCBI chr 2:210,522,370...210,550,546
Ensembl chr 2:210,522,375...210,550,560
|
|
G |
Csf2 |
colony stimulating factor 2 |
affects activity increases expression |
ISO EXP |
CSF2 protein affects the activity of Cyclophosphamide Cyclophosphamide results in increased expression of CSF2 protein |
CTD |
PMID:8349185 PMID:18848347 |
|
NCBI chr10:39,602,089...39,604,070
Ensembl chr10:39,602,089...39,604,070
|
|
G |
Csk |
C-terminal Src kinase |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CSK mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 8:62,405,714...62,424,707
Ensembl chr 8:62,405,715...62,424,303
|
|
G |
Cst7 |
cystatin F |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CST7 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 3:146,363,913...146,373,365
Ensembl chr 3:146,365,092...146,373,365
|
|
G |
Csta |
cystatin A |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of CSTA mRNA |
CTD |
PMID:24356939 |
|
NCBI chr11:67,555,792...67,566,980
Ensembl chr11:67,555,658...67,566,972
|
|
G |
Cth |
cystathionine gamma-lyase |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CTH protein |
CTD |
PMID:29129814 |
|
NCBI chr 2:264,266,959...264,293,040
Ensembl chr 2:264,266,984...264,293,046
|
|
G |
Ctnnbip1 |
catenin, beta-interacting protein 1 |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of CTNNBIP1 mRNA |
CTD |
PMID:16322899 |
|
NCBI chr 5:166,464,170...166,513,030
Ensembl chr 5:166,464,252...166,513,027
|
|
G |
Ctnnd2 |
catenin delta 2 |
multiple interactions |
ISO |
CTNND2 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr 2:83,227,247...84,094,315
Ensembl chr 2:83,393,282...84,094,315
|
|
G |
Ctsd |
cathepsin D |
multiple interactions increases activity |
ISO EXP |
[Cyclophosphamide co-treated with Mecamylamine] results in increased expression of CTSD mRNA Cyclophosphamide results in increased activity of CTSD protein Anthocyanins inhibits the reaction [Cyclophosphamide results in increased activity of CTSD protein]; Plant Extracts inhibits the reaction [Cyclophosphamide results in increased activity of CTSD protein] |
CTD |
PMID:18433785 PMID:25451569 |
|
NCBI chr 1:215,541,570...215,553,446
Ensembl chr 1:215,541,542...215,553,451
|
|
G |
Ctsh |
cathepsin H |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CTSH mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 8:97,439,155...97,458,293
Ensembl chr 8:97,439,161...97,458,287
|
|
G |
Ctsl |
cathepsin L |
increases expression decreases expression multiple interactions |
ISO |
Cyclophosphamide results in increased expression of CTSL mRNA Cyclophosphamide results in decreased expression of CTSL mRNA 5-(N-methyl-N-propargylaminomethyl)-8-hydroxyquinoline inhibits the reaction [Cyclophosphamide results in decreased expression of CTSL mRNA] |
CTD |
PMID:17403535 PMID:30760223 |
|
NCBI chr17:1,873,105...1,879,266
Ensembl chr17:1,872,848...1,879,279
|
|
G |
Cx3cl1 |
C-X3-C motif chemokine ligand 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of CX3CL1 protein |
CTD |
PMID:16651033 |
|
NCBI chr19:10,644,267...10,654,861
Ensembl chr19:10,644,244...10,653,800
|
|
G |
Cx3cr1 |
C-X3-C motif chemokine receptor 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of CX3CR1 protein |
CTD |
PMID:16651033 |
|
NCBI chr 8:128,740,756...128,754,514
Ensembl chr 8:128,740,756...128,754,514
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of CXCL1 protein |
CTD |
PMID:18848347 |
|
NCBI chr14:18,743,678...18,745,457
Ensembl chr14:18,743,685...18,745,457
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
affects expression increases expression increases response to substance |
ISO |
Cyclophosphamide affects the expression of CXCL10 mRNA Cyclophosphamide results in increased expression of CXCL10 protein CXCL10 protein results in increased susceptibility to Cyclophosphamide |
CTD |
PMID:18957084 |
|
NCBI chr14:17,210,733...17,212,930
Ensembl chr14:17,210,733...17,212,930
|
|
G |
Cxcl11 |
C-X-C motif chemokine ligand 11 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CXCL11 protein |
CTD |
PMID:18957084 |
|
NCBI chr14:17,195,395...17,198,170
Ensembl chr14:17,195,014...17,198,291
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
affects expression increases expression |
ISO EXP |
Cyclophosphamide affects the expression of CXCL12 mRNA Cyclophosphamide results in increased expression of CXCL12 mRNA; Cyclophosphamide results in increased expression of CXCL12 protein |
CTD |
PMID:12624490 PMID:16337237 PMID:19066630 PMID:20032115 |
|
NCBI chr 4:149,261,044...149,273,891
Ensembl chr 4:149,261,044...149,273,891
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
increases expression affects expression multiple interactions |
ISO |
Cyclophosphamide results in increased expression of CXCL1 mRNA; Cyclophosphamide results in increased expression of CXCL1 protein Cyclophosphamide affects the expression of CXCL3 mRNA VIP protein inhibits the reaction [Cyclophosphamide results in increased expression of CXCL1 protein] |
CTD |
PMID:15331540 PMID:18483878 PMID:18957084 |
|
NCBI chr14:18,820,168...18,839,659
Ensembl chr14:18,820,168...18,839,595
|
|
G |
Cxcl6 |
C-X-C motif chemokine ligand 6 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CXCL5 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr14:18,860,201...18,920,839
Ensembl chr14:18,860,264...18,862,407
|
|
G |
Cxcl9 |
C-X-C motif chemokine ligand 9 |
affects expression decreases expression increases expression |
ISO |
Cyclophosphamide affects the expression of CXCL9 mRNA Cyclophosphamide results in decreased expression of CXCL9 protein Cyclophosphamide results in increased expression of CXCL9 mRNA; Cyclophosphamide results in increased expression of CXCL9 protein |
CTD |
PMID:15331540 PMID:18957084 PMID:21041162 PMID:21880982 |
|
NCBI chr14:17,228,832...17,233,743
Ensembl chr14:17,228,856...17,234,712
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
multiple interactions decreases expression increases expression affects localization |
EXP ISO |
Cyclophosphamide promotes the reaction [MIF protein binds to CXCR4 protein] Cyclophosphamide results in decreased expression of CXCR4 mRNA Cyclophosphamide results in increased expression of CXCR4 mRNA; Cyclophosphamide results in increased expression of CXCR4 protein Cyclophosphamide affects the localization of CXCR4 protein |
CTD |
PMID:19066630 PMID:20032115 PMID:21041162 |
|
NCBI chr13:45,314,952...45,318,856
Ensembl chr13:45,314,933...45,318,878
|
|
G |
Cxcr6 |
C-X-C motif chemokine receptor 6 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CXCR6 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 8:132,869,712...132,870,766
Ensembl chr 8:132,869,712...132,870,767
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity |
ISO |
Cyclophosphamide results in decreased activity of CYP1A1 protein |
CTD |
PMID:18420780 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases activity |
ISO |
Cyclophosphamide results in decreased activity of CYP1A2 protein |
CTD |
PMID:18420780 |
|
NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CYP1B1 mRNA |
CTD |
PMID:12167460 |
|
NCBI chr 6:2,308,179...2,316,739
Ensembl chr 6:2,307,808...2,316,722
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
multiple interactions increases expression increases response to substance affects metabolic processing increases activity increases hydroxylation increases metabolic processing |
EXP ISO |
Cyclophosphamide results in increased expression of and results in increased activity of CYP2B1 protein; Metyrapone inhibits the reaction [CYP2B1 results in increased susceptibility to Cyclophosphamide] Cyclophosphamide results in increased expression of CYP2B10 mRNA CYP2B1 protein results in increased susceptibility to Cyclophosphamide; CYP2B1 results in increased susceptibility to Cyclophosphamide CYP2B1 protein affects the metabolism of Cyclophosphamide CYP2B1 results in increased activity of Cyclophosphamide CYP2B1 protein mutant form results in increased hydroxylation of Cyclophosphamide; CYP2B1 protein results in increased hydroxylation of Cyclophosphamide Cyclophosphamide results in increased expression of CYP2B1 mRNA; Cyclophosphamide results in increased expression of CYP2B1 protein CYP2B1 protein results in increased metabolism of Cyclophosphamide; CYP2B1 results in increased metabolism of Cyclophosphamide |
CTD |
PMID:2272335 PMID:7834628 PMID:8640822 PMID:9592392 PMID:10415877 PMID:11221871 PMID:11933215 PMID:15102956 PMID:15635577 PMID:16019949 PMID:17634551 PMID:19103281 PMID:20566340 PMID:24819615 |
|
NCBI chr 7:99,142,431...99,183,540
Ensembl chr 7:99,142,450...99,181,783
|
|
G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of CYP2B2 mRNA; Cyclophosphamide results in increased expression of CYP2B2 protein |
CTD |
PMID:16019949 PMID:17634551 |
|
NCBI chr 1:83,103,925...83,119,578
Ensembl chr 1:83,103,925...83,119,193
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
multiple interactions increases metabolic processing increases activity increases response to substance increases hydroxylation affects hydroxylation |
ISO EXP |
[Cyclophosphamide results in increased activity of NR1I3 protein alternative form] which results in increased expression of CYP2B6 mRNA; [Doxorubicin co-treated with Cyclophosphamide] affects the expression of CYP2B6 mRNA; Cyclophosphamide results in decreased expression of and results in decreased activity of CYP2B6 protein; CYP2B6 protein polymorphism affects the activity of and affects the susceptibility to Cyclophosphamide; CYP2B6 protein results in increased metabolism of and results in increased susceptibility to Cyclophosphamide; POR promotes the reaction [CYP2B6 results in increased susceptibility to Cyclophosphamide]; POR protein promotes the reaction [CYP2B6 protein results in increased susceptibility to Cyclophosphamide] CYP2B6 protein results in increased metabolism of Cyclophosphamide CYP2B6 protein results in increased activity of Cyclophosphamide CYP2B6 protein results in increased susceptibility to Cyclophosphamide; CYP2B6 results in increased susceptibility to Cyclophosphamide CYP2B6 protein results in increased hydroxylation of Cyclophosphamide CYP2B6 intron polymorphism affects the hydroxylation of Cyclophosphamide; CYP2B6 promoter polymorphism affects the hydroxylation of Cyclophosphamide |
CTD |
PMID:9766669 PMID:10919648 PMID:11389073 PMID:11723234 PMID:12498089 PMID:12872138 PMID:15248218 PMID:15769884 PMID:16183265 PMID:16322899 PMID:17041008 PMID:17502835 PMID:18212249 PMID:18633247 PMID:24819615 PMID:25860621 |
|
NCBI chr 1:83,163,103...83,236,615
Ensembl chr 1:83,163,079...83,236,615
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
increases expression increases metabolic processing increases response to substance increases activity multiple interactions |
EXP ISO |
Cyclophosphamide results in increased expression of CYP2C11 mRNA CYP2C9 protein results in increased metabolism of Cyclophosphamide CYP2C9 protein results in increased susceptibility to Cyclophosphamide CYP2C9 results in increased activity of Cyclophosphamide [GSTM1 protein co-treated with CYP2C9 protein] results in increased susceptibility to [Busulfan co-treated with Cyclophosphamide]; Sulfaphenazole inhibits the reaction [CYP2C9 protein results in increased susceptibility to Cyclophosphamide] CYP2C11 results in increased metabolism of Cyclophosphamide |
CTD |
PMID:9241661 PMID:10991840 PMID:11377097 PMID:16019949 PMID:20566340 PMID:24819615 PMID:28744217 |
|
NCBI chr 1:257,676,172...258,004,428
Ensembl chr 1:257,970,345...258,004,434
|
|
G |
Cyp2c24 |
cytochrome P450, family 2, subfamily c, polypeptide 24 |
multiple interactions increases response to substance increases activity |
ISO |
POR promotes the reaction [CYP2C18 results in increased susceptibility to Cyclophosphamide] CYP2C18 results in increased activity of Cyclophosphamide |
CTD |
PMID:9241661 PMID:9766669 |
|
NCBI chr 1:258,074,797...258,139,176
Ensembl chr 1:258,074,860...258,139,176
|
|
G |
Cyp2c6v1 |
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 |
increases metabolic processing increases response to substance increases hydroxylation increases activity multiple interactions decreases metabolic processing |
EXP ISO |
CYP2C6V1 results in increased metabolism of Cyclophosphamide CYP2C19 protein results in increased susceptibility to Cyclophosphamide CYP2C19 protein results in increased hydroxylation of Cyclophosphamide CYP2C19 results in increased activity of Cyclophosphamide CYP2C19 protein results in increased metabolism of Cyclophosphamide [CYP2C19 protein results in increased hydroxylation of Cyclophosphamide] which results in increased chemical synthesis of 4-hydroxycyclophosphamide; [CYP2C19 protein results in increased hydroxylation of Cyclophosphamide] which results in increased chemical synthesis of Acrolein; CYP2C19 protein polymorphism affects the activity of and affects the susceptibility to Cyclophosphamide CYP2C19 gene polymorphism results in decreased metabolism of Cyclophosphamide |
CTD |
PMID:9241661 PMID:15248218 PMID:16116487 PMID:20566340 PMID:30500380 |
|
NCBI chr 1:147,713,879...147,814,410
Ensembl chr 1:147,713,892...147,888,007
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
increases activity increases expression |
ISO |
CYP2C8 results in increased activity of Cyclophosphamide Cyclophosphamide results in increased expression of CYP2C29 mRNA |
CTD |
PMID:9241661 PMID:24819615 |
|
NCBI chr 1:147,236,480...147,307,988
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
increases metabolic processing |
ISO |
CYP2D6 protein results in increased metabolism of Cyclophosphamide |
CTD |
PMID:11377097 |
|
NCBI chr 7:123,599,264...123,608,436
Ensembl chr 7:123,599,266...123,608,436
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
increases metabolic processing |
EXP |
CYP2E1 results in increased metabolism of Cyclophosphamide |
CTD |
PMID:20566340 |
|
NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of CYP3A2 mRNA; Cyclophosphamide results in increased expression of CYP3A2 protein |
CTD |
PMID:16019949 |
|
NCBI chr12:11,641,500...11,677,818
Ensembl chr12:11,655,402...11,733,136
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
affects expression decreases expression |
EXP |
Cyclophosphamide affects the expression of CYP3A23-3A1 mRNA Cyclophosphamide results in decreased expression of CYP3A23-3A1 mRNA |
CTD |
PMID:18246545 |
|
NCBI chr12:11,053,888...11,082,742
Ensembl chr12:11,655,402...11,733,136
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
increases metabolic processing decreases activity affects response to substance increases expression affects metabolic processing increases response to substance multiple interactions increases hydroxylation |
ISO |
CYP3A4 protein results in increased metabolism of Cyclophosphamide Cyclophosphamide results in decreased activity of CYP3A4 protein CYP3A4 gene polymorphism affects the susceptibility to Cyclophosphamide Cyclophosphamide results in increased expression of CYP3A4 mRNA CYP3A4 protein affects the metabolism of Cyclophosphamide CYP3A4 protein results in increased susceptibility to Cyclophosphamide [Cyclophosphamide results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; [CYP3A4 protein results in increased hydroxylation of Cyclophosphamide] which results in increased chemical synthesis of 4-hydroxycyclophosphamide; [CYP3A4 protein results in increased hydroxylation of Cyclophosphamide] which results in increased chemical synthesis of Acrolein; CYP3A4 gene affects the susceptibility to [Carmustine co-treated with Cyclophosphamide co-treated with Cisplatin]; CYP3A4 protein results in increased metabolism of and results in increased susceptibility to Cyclophosphamide |
CTD |
PMID:11377097 PMID:16087946 PMID:17041008 PMID:18420780 PMID:18839173 PMID:25860621 PMID:26718876 PMID:30500380 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
affects metabolic processing increases expression multiple interactions affects response to substance |
ISO |
CYP3A5 protein affects the metabolism of Cyclophosphamide Cyclophosphamide results in increased expression of CYP3A13 mRNA CYP3A5 gene affects the susceptibility to [Carmustine co-treated with Cyclophosphamide co-treated with Cisplatin] CYP3A5 gene polymorphism affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16087946 PMID:24819615 |
|
NCBI chr12:19,074,288...19,114,491
Ensembl chr12:19,074,583...19,114,399
|
|
G |
Dcn |
decorin |
multiple interactions |
ISO |
DCN protein inhibits the reaction [TGFB1 protein results in decreased susceptibility to [Cyclophosphamide co-treated with Cisplatin co-treated with Melphalan co-treated with Thiotepa]] |
CTD |
PMID:9509296 |
|
NCBI chr 7:38,742,250...38,782,282
Ensembl chr 7:38,742,051...38,782,323
|
|
G |
Ddb1 |
damage-specific DNA binding protein 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of DDB1 mRNA |
CTD |
PMID:11056294 |
|
NCBI chr 1:226,657,561...226,683,356
Ensembl chr 1:226,657,561...226,683,347
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
affects expression increases expression multiple interactions decreases expression |
EXP ISO |
Cyclophosphamide affects the expression of DDIT3 mRNA Cyclophosphamide results in increased expression of DDIT3 mRNA; Cyclophosphamide results in increased expression of DDIT3 protein sacubitril-valsartan inhibits the reaction [Cyclophosphamide results in increased expression of DDIT3 mRNA]; sacubitril-valsartan inhibits the reaction [Cyclophosphamide results in increased expression of DDIT3 protein]; Valsartan inhibits the reaction [Cyclophosphamide results in increased expression of DDIT3 mRNA]; Valsartan inhibits the reaction [Cyclophosphamide results in increased expression of DDIT3 protein] Cyclophosphamide metabolite results in decreased expression of DDIT3 mRNA |
CTD |
PMID:18246545 PMID:24356939 PMID:32197949 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
affects response to substance |
ISO |
DDIT4 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr20:29,509,283...29,511,382
Ensembl chr20:29,509,289...29,511,382
|
|
G |
Deaf1 |
DEAF1 transcription factor |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of DEAF1 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 1:214,283,787...214,317,466
Ensembl chr 1:214,283,790...214,317,466
|
|
G |
Dlc1 |
DLC1 Rho GTPase activating protein |
increases expression |
ISO |
Cyclophosphamide results in increased expression of DLC1 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr16:58,776,489...59,247,752
Ensembl chr16:59,077,574...59,247,754
|
|
G |
Dnajb1 |
DnaJ heat shock protein family (Hsp40) member B1 |
affects expression increases expression |
EXP ISO |
Cyclophosphamide affects the expression of DNAJB1 mRNA Cyclophosphamide metabolite results in increased expression of DNAJB1 mRNA |
CTD |
PMID:18246545 PMID:24356939 |
|
NCBI chr19:24,747,178...24,750,919
Ensembl chr19:24,747,178...24,750,919
|
|
G |
Dnajb4 |
DnaJ heat shock protein family (Hsp40) member B4 |
increases expression |
ISO |
Cyclophosphamide metabolite results in increased expression of DNAJB4 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 2:257,394,692...257,425,344
Ensembl chr 2:257,394,818...257,425,242
|
|
G |
Dnajb6 |
DnaJ heat shock protein family (Hsp40) member B6 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of DNAJB6 protein |
CTD |
PMID:17475930 |
|
NCBI chr 4:2,711,329...2,774,969
Ensembl chr 4:2,711,385...2,774,890
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
multiple interactions increases expression decreases methylation |
ISO |
Cyclophosphamide promotes the reaction [KDM1A protein results in decreased methylation of and results in decreased degradation of DNMT1 protein] Cyclophosphamide results in increased expression of DNMT1 protein Cyclophosphamide results in decreased methylation of DNMT1 protein |
CTD |
PMID:22007908 |
|
NCBI chr 8:21,922,515...21,968,495
Ensembl chr 8:21,922,515...21,968,495
|
|
G |
Dntt |
DNA nucleotidylexotransferase |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of DNTT mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 1:260,289,626...260,321,174
Ensembl chr 1:260,289,589...260,321,320
|
|
G |
Dpf3 |
double PHD fingers 3 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of DPF3 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 6:106,660,569...106,971,310
Ensembl chr 6:106,721,349...106,971,250
|
|
G |
Dpysl4 |
dihydropyrimidinase-like 4 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of DPYSL4 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 1:211,423,022...211,438,533
Ensembl chr 1:211,423,022...211,438,531
|
|
G |
Drd1 |
dopamine receptor D1 |
affects binding |
ISO |
Cyclophosphamide binds to DRD1 protein |
CTD |
PMID:11180191 |
|
NCBI chr17:11,099,736...11,104,352
Ensembl chr17:11,101,306...11,103,541
|
|
G |
Drd2 |
dopamine receptor D2 |
affects binding |
ISO |
Cyclophosphamide binds to DRD2 protein |
CTD |
PMID:11180191 |
|
NCBI chr 8:53,678,777...53,743,643
Ensembl chr 8:53,678,777...53,743,642
|
|
G |
Dusp10 |
dual specificity phosphatase 10 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of DUSP10 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr13:104,284,660...104,321,455
Ensembl chr13:104,284,660...104,321,455
|
|
G |
Dusp2 |
dual specificity phosphatase 2 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of DUSP2 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 3:119,776,925...119,779,110
Ensembl chr 3:119,776,925...119,779,099
|
|
G |
Dzip1 |
DAZ interacting zinc finger protein 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of DZIP1 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr15:104,117,551...104,168,574
Ensembl chr15:104,117,556...104,170,958
|
|
G |
E2f3 |
E2F transcription factor 3 |
multiple interactions |
ISO |
E2F3 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr17:36,334,136...36,408,831
Ensembl chr17:36,334,147...36,408,831
|
|
G |
Eda2r |
ectodysplasin A2 receptor |
increases expression |
ISO |
Cyclophosphamide results in increased expression of EDA2R mRNA |
CTD |
PMID:21527772 |
|
NCBI chr X:66,560,200...66,602,509
Ensembl chr X:66,561,286...66,602,506
|
|
G |
Edn1 |
endothelin 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of EDN1 protein |
CTD |
PMID:17562616 PMID:18548196 |
|
NCBI chr17:22,136,814...22,143,745
Ensembl chr17:22,137,324...22,143,324
|
|
G |
Ednrb |
endothelin receptor type B |
increases expression |
ISO |
Cyclophosphamide results in increased expression of EDNRB mRNA |
CTD |
PMID:20849824 |
|
NCBI chr15:88,004,775...88,036,354
Ensembl chr15:88,006,977...88,036,354
|
|
G |
Eef2 |
eukaryotic translation elongation factor 2 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of EEF2 mRNA |
CTD |
PMID:18246545 |
|
NCBI chr 7:11,401,501...11,406,771
Ensembl chr 7:11,401,501...11,406,771
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
EGFR protein affects the susceptibility to [Cyclophosphamide co-treated with Doxorubicin co-treated with Fluorouracil] |
CTD |
PMID:15981280 |
|
NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
|
|
G |
Egr1 |
early growth response 1 |
increases expression multiple interactions decreases expression |
ISO EXP |
Cyclophosphamide results in increased expression of EGR1 mRNA 3-cyanoalanine inhibits the reaction [[N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine co-treated with Cyclophosphamide] results in increased expression of EGR1 protein]; [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine co-treated with Cyclophosphamide] results in increased expression of EGR1 protein Cyclophosphamide results in increased expression of EGR1 protein Cyclophosphamide results in decreased expression of EGR1 mRNA |
CTD |
PMID:7498375 PMID:9776515 PMID:21041162 PMID:21527772 PMID:29129814 |
|
NCBI chr18:27,657,903...27,660,101
Ensembl chr18:27,657,628...27,661,429
|
|
G |
Egr2 |
early growth response 2 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of EGR2 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr20:22,452,170...22,461,018
Ensembl chr20:22,454,463...22,459,025
|
|
G |
Egr4 |
early growth response 4 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of EGR4 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 4:117,293,620...117,296,082
Ensembl chr 4:117,293,620...117,296,082
|
|
G |
Eif1ax |
eukaryotic translation initiation factor 1A, X-linked |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of EIF1AX mRNA |
CTD |
PMID:16322899 |
|
NCBI chr X:37,579,959...37,595,300
Ensembl chr X:37,579,957...37,595,486
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
increases phosphorylation multiple interactions |
EXP |
Cyclophosphamide results in increased phosphorylation of EIF2AK3 protein sacubitril-valsartan inhibits the reaction [Cyclophosphamide results in increased phosphorylation of EIF2AK3 protein]; Valsartan inhibits the reaction [Cyclophosphamide results in increased phosphorylation of EIF2AK3 protein] |
CTD |
PMID:32197949 |
|
NCBI chr 4:98,648,513...98,709,695
Ensembl chr 4:98,648,545...98,709,694
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of EIF4EBP1 mRNA |
CTD |
PMID:16322899 |
|
NCBI chr16:68,954,860...68,968,248
Ensembl chr16:68,954,875...68,968,248
|
|
G |
Elovl2 |
ELOVL fatty acid elongase 2 |
affects response to substance |
ISO |
ELOVL2 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr17:21,382,461...21,422,413
Ensembl chr17:21,382,455...21,422,407
|
|
G |
Emp1 |
epithelial membrane protein 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of EMP1 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 4:169,161,076...169,181,967
Ensembl chr 4:169,147,243...169,181,966
|
|
G |
Emp3 |
epithelial membrane protein 3 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of EMP3 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 1:101,900,731...101,903,948
Ensembl chr 1:101,900,733...101,903,910
|
|
G |
Epb41l2 |
erythrocyte membrane protein band 4.1-like 2 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of EPB41L2 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 1:20,881,820...21,067,713
Ensembl chr 1:20,893,995...20,962,526
|
|
G |
Ephx1 |
epoxide hydrolase 1 |
affects expression increases expression |
EXP |
Cyclophosphamide affects the expression of EPHX1 mRNA Cyclophosphamide results in increased expression of EPHX1 mRNA |
CTD |
PMID:18246545 |
|
NCBI chr13:99,271,390...99,300,580
Ensembl chr13:99,271,366...99,300,579
|
|
G |
Epo |
erythropoietin |
multiple interactions increases response to substance decreases expression |
EXP |
angelicae sinensis extract inhibits the reaction [Cyclophosphamide results in decreased expression of EPO mRNA]; Astragali compound inhibits the reaction [Cyclophosphamide results in decreased expression of EPO mRNA] EPO protein results in increased susceptibility to Cyclophosphamide |
CTD |
PMID:11245434 PMID:19627214 |
|
NCBI chr12:22,274,828...22,278,268
Ensembl chr12:22,274,828...22,278,266
|
|
G |
Erap1 |
endoplasmic reticulum aminopeptidase 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of ERAP1 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 2:1,410,877...1,449,734
Ensembl chr 2:1,410,934...1,449,733
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
multiple interactions |
ISO |
ERBB2 affects the susceptibility to [Doxorubicin co-treated with Cyclophosphamide co-treated with docetaxel]; ERBB2 protein affects the susceptibility to [Cyclophosphamide co-treated with Doxorubicin co-treated with docetaxel]; ERBB2 protein affects the susceptibility to [Cyclophosphamide co-treated with pirarubicin co-treated with Fluorouracil]; ERBB2 protein affects the susceptibility to [Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide]; ERBB2 protein affects the susceptibility to [Fluorouracil co-treated with Epirubicin co-treated with Cyclophosphamide]; ERBB2 protein results in decreased susceptibility to [Cyclophosphamide co-treated with Thiotepa co-treated with Carboplatin] |
CTD |
PMID:9816327 PMID:15834928 PMID:15940066 PMID:16446318 PMID:16682728 PMID:17010609 |
|
NCBI chr10:86,367,596...86,391,728
Ensembl chr10:86,367,596...86,391,728
|
|
G |
Erbb4 |
erb-b2 receptor tyrosine kinase 4 |
multiple interactions |
ISO |
ERBB4 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr 9:75,021,790...76,178,936
Ensembl chr 9:75,021,790...75,528,644
|
|
G |
Ercc1 |
ERCC excision repair 1, endonuclease non-catalytic subunit |
affects expression |
EXP |
Cyclophosphamide affects the expression of ERCC1 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 1:80,256,973...80,268,198
Ensembl chr 1:80,256,973...80,268,198
|
|
G |
Ercc2 |
ERCC excision repair 2, TFIIH core complex helicase subunit |
affects expression increases expression multiple interactions |
EXP ISO |
Cyclophosphamide affects the expression of ERCC2 mRNA Cyclophosphamide results in increased expression of ERCC2 mRNA 5-(N-methyl-N-propargylaminomethyl)-8-hydroxyquinoline inhibits the reaction [Cyclophosphamide results in increased expression of ERCC2 mRNA] |
CTD |
PMID:11906922 PMID:30760223 |
|
NCBI chr 1:80,293,574...80,307,334
Ensembl chr 1:80,293,566...80,307,344
|
|
G |
Erg |
ETS transcription factor ERG |
increases expression |
ISO |
Cyclophosphamide results in increased expression of ERG mRNA |
CTD |
PMID:17403535 |
|
NCBI chr11:35,645,317...35,749,637
Ensembl chr11:35,646,116...35,749,594
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
increases phosphorylation multiple interactions |
EXP |
Cyclophosphamide results in increased phosphorylation of ERN1 protein sacubitril-valsartan inhibits the reaction [Cyclophosphamide results in increased phosphorylation of ERN1 protein]; Valsartan inhibits the reaction [Cyclophosphamide results in increased phosphorylation of ERN1 protein] |
CTD |
PMID:32197949 |
|
NCBI chr10:94,588,555...94,682,072
Ensembl chr10:94,588,555...94,681,914
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] results in increased expression of ESR1 mRNA |
CTD |
PMID:16322899 |
|
NCBI chr 1:41,192,029...41,594,799
Ensembl chr 1:41,192,824...41,594,796
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] results in increased expression of ESR2 mRNA |
CTD |
PMID:16322899 |
|
NCBI chr 6:99,163,953...99,214,711
Ensembl chr 6:99,164,357...99,214,251
|
|
G |
Esrra |
estrogen related receptor, alpha |
decreases expression increases expression |
EXP |
Cyclophosphamide results in decreased expression of ESRRA mRNA Cyclophosphamide results in increased expression of ESRRA mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 1:222,168,729...222,178,842
Ensembl chr 1:222,168,730...222,178,725
|
|
G |
Evi2a |
ecotropic viral integration site 2A |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of EVI2A mRNA |
CTD |
PMID:24356939 |
|
NCBI chr10:66,870,048...66,873,948
Ensembl chr10:66,870,067...66,873,948
|
|
G |
F2rl1 |
F2R like trypsin receptor 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of F2RL1 protein |
CTD |
PMID:15643279 |
|
NCBI chr 2:25,222,324...25,235,275
Ensembl chr 2:25,222,328...25,235,275
|
|
G |
F2rl2 |
coagulation factor II (thrombin) receptor-like 2 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of F2RL2 protein |
CTD |
PMID:15643279 |
|
NCBI chr 2:26,240,385...26,245,533
Ensembl chr 2:26,240,385...26,245,533
|
|
G |
F2rl3 |
F2R like thrombin or trypsin receptor 3 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of F2RL3 protein |
CTD |
PMID:15643279 |
|
NCBI chr16:18,817,797...18,819,790
Ensembl chr16:18,814,622...18,819,833
|
|
G |
F3 |
coagulation factor III, tissue factor |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of F3 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 2:225,310,686...225,322,281
Ensembl chr 2:225,310,624...225,322,272
|
|
G |
Fam107b |
family with sequence similarity 107, member B |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of FAM107B mRNA |
CTD |
PMID:24356939 |
|
NCBI chr17:78,489,667...78,689,933
Ensembl chr17:78,489,668...78,561,613
|
|
G |
Fam234b |
family with sequence similarity 234, member B |
multiple interactions |
ISO |
FAM234B mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr 4:168,976,797...169,052,750
Ensembl chr 4:168,976,859...169,019,561
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions decreases expression increases expression |
ISO EXP |
[Cyclophosphamide co-treated with cacalol] results in decreased expression of FAS protein; [Cyclophosphamide co-treated with NAc-Sar-Gly-Val-(d-allo-Ile)-Thr-Nva-Ile-Arg-ProNEt] results in increased expression of FAS Plant Extracts inhibits the reaction [Cyclophosphamide results in increased expression of FAS mRNA] Cyclophosphamide metabolite results in decreased expression of FAS mRNA Cyclophosphamide results in increased expression of FAS mRNA; Cyclophosphamide results in increased expression of FAS protein |
CTD |
PMID:10393266 PMID:16166447 PMID:20665104 PMID:24356939 PMID:25446862 |
|
NCBI chr 1:252,589,785...252,624,790
Ensembl chr 1:252,589,785...252,624,790
|
|
G |
Faslg |
Fas ligand |
multiple interactions |
ISO |
[Cyclophosphamide co-treated with NAc-Sar-Gly-Val-(d-allo-Ile)-Thr-Nva-Ile-Arg-ProNEt] results in increased expression of FASLG |
CTD |
PMID:16166447 |
|
NCBI chr13:79,696,811...79,717,581
Ensembl chr13:79,698,445...79,705,705
|
|
G |
Fau |
FAU, ubiquitin like and ribosomal protein S30 fusion |
increases expression |
EXP |
Cyclophosphamide results in increased expression of FAU mRNA |
CTD |
PMID:11599041 |
|
NCBI chr 1:221,420,312...221,421,827
Ensembl chr 1:221,420,271...221,421,842
|
|
G |
Fbxo40 |
F-box protein 40 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of FBXO40 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr11:66,713,913...66,731,195
Ensembl chr11:66,713,888...66,731,198
|
|
G |
Fbxw7 |
F-box and WD repeat domain containing 7 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of FBXW7 mRNA |
CTD |
PMID:29445054 |
|
NCBI chr 2:184,230,191...184,309,805
Ensembl chr 2:184,231,260...184,309,664
|
|
G |
Fcer1g |
Fc fragment of IgE receptor Ig |
increases expression |
ISO |
Cyclophosphamide results in increased expression of FCER1G mRNA |
CTD |
PMID:21041162 |
|
NCBI chr13:89,601,894...89,606,326
Ensembl chr13:89,601,896...89,606,326
|
|
G |
Fcgr2a |
Fc fragment of IgG receptor IIa |
increases expression |
ISO |
Cyclophosphamide results in increased expression of FCGR3 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr13:91,146,878...91,163,691
Ensembl chr13:91,168,973...91,198,036 Ensembl chr13:91,168,973...91,198,036
|
|
G |
Fcgrt |
Fc fragment of IgG receptor and transporter |
increases expression |
ISO |
Cyclophosphamide results in increased expression of FCGRT mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 1:101,086,872...101,096,159
Ensembl chr 1:101,086,877...101,095,594
|
|
G |
Fhl1 |
four and a half LIM domains 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of FHL1 mRNA |
CTD |
PMID:23558518 |
|
NCBI chr X:159,112,516...159,172,528
Ensembl chr X:159,112,880...159,172,524
|
|
G |
Fkbp1b |
FKBP prolyl isomerase 1B |
affects response to substance |
ISO |
FKBP1B protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr 6:29,975,863...29,987,252
Ensembl chr 6:29,977,797...29,987,451
|
|
G |
Fkbpl |
FKBP prolyl isomerase like |
increases expression |
ISO |
Cyclophosphamide results in increased expression of FKBPL mRNA |
CTD |
PMID:14503796 |
|
NCBI chr20:4,411,890...4,413,360
Ensembl chr20:4,411,876...4,413,366
|
|
G |
Flnc |
filamin C |
increases expression |
ISO |
Cyclophosphamide results in increased expression of FLNC mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 4:56,710,934...56,738,779
Ensembl chr 4:56,711,049...56,738,791
|
|
G |
Flt3lg |
Fms related receptor tyrosine kinase 3 ligand |
affects expression |
ISO |
Cyclophosphamide affects the expression of FLT3L mRNA |
CTD |
PMID:12624490 |
|
NCBI chr 1:101,126,006...101,131,413
Ensembl chr 1:101,124,479...101,131,413
|
|
G |
Fndc3b |
fibronectin type III domain containing 3B |
affects response to substance |
ISO |
FNDC3B protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr 2:113,109,949...113,415,171
Ensembl chr 2:113,112,902...113,345,577
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
ISO EXP |
Capsaicin inhibits the reaction [Cyclophosphamide results in increased expression of FOS mRNA] Cyclophosphamide results in increased expression of FOS protein alfuzosin inhibits the reaction [Cyclophosphamide results in increased expression of FOS protein]; Capsaicin inhibits the reaction [Cyclophosphamide results in increased expression of FOS protein]; resiniferatoxin inhibits the reaction [Cyclophosphamide results in increased expression of FOS protein] |
CTD |
PMID:7498375 PMID:8801120 PMID:8808730 PMID:9776515 PMID:10749792 PMID:15099680 PMID:15217452 PMID:17240043 PMID:18093676 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Foxp3 |
forkhead box P3 |
decreases expression multiple interactions |
ISO |
Cyclophosphamide results in decreased expression of FOXP3 mRNA; Cyclophosphamide results in decreased expression of FOXP3 protein Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of FOXP3 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of FOXP3 protein] |
CTD |
PMID:15591121 PMID:32151603 |
|
NCBI chr X:15,753,175...15,768,648
Ensembl chr X:15,753,175...15,768,522
|
|
G |
Foxp4 |
forkhead box P4 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of FOXP4 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 9:15,068,378...15,124,962
Ensembl chr 9:15,068,399...15,125,318
|
|
G |
Fpr2 |
formyl peptide receptor 2 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of FPR2 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 1:59,800,558...59,809,507
Ensembl chr 1:59,800,984...59,802,401
|
|
G |
Fscn1 |
fascin actin-bundling protein 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of FSCN1 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr12:13,655,459...13,668,595
Ensembl chr12:13,656,554...13,668,515
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
increases expression multiple interactions decreases secretion |
ISO EXP |
Cyclophosphamide results in increased expression of FSHB protein sacubitril-valsartan inhibits the reaction [Cyclophosphamide results in decreased secretion of FSHB protein]; Valsartan inhibits the reaction [Cyclophosphamide results in decreased secretion of FSHB protein] |
CTD |
PMID:6788612 PMID:25446862 PMID:32197949 |
|
NCBI chr 3:98,088,321...98,092,131
Ensembl chr 3:98,088,324...98,092,131
|
|
G |
Fshr |
follicle stimulating hormone receptor |
multiple interactions decreases expression |
ISO |
coenzyme Q10 inhibits the reaction [Cyclophosphamide results in decreased expression of FSHR mRNA] |
CTD |
PMID:31557371 |
|
NCBI chr 6:12,796,383...12,997,817
Ensembl chr 6:12,796,383...12,997,817
|
|
G |
Fyn |
FYN proto-oncogene, Src family tyrosine kinase |
increases expression |
ISO |
Cyclophosphamide results in increased expression of FYN mRNA |
CTD |
PMID:17403535 |
|
NCBI chr20:44,436,354...44,630,316
Ensembl chr20:44,436,403...44,630,317
|
|
G |
G3bp1 |
G3BP stress granule assembly factor 1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of G3BP1 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr10:40,812,858...40,846,252
Ensembl chr10:40,812,858...40,846,252
|
|
G |
G6pc2 |
glucose-6-phosphatase catalytic subunit 2 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of G6PC2 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 3:55,464,528...55,467,170
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
increases expression affects expression |
EXP ISO |
Cyclophosphamide results in increased expression of GADD45A mRNA Cyclophosphamide affects the expression of GADD45A mRNA |
CTD |
PMID:18246545 PMID:29445054 |
|
NCBI chr 4:97,782,512...97,784,814
Ensembl chr 4:97,782,512...97,784,842
|
|
G |
Gal |
galanin and GMAP prepropeptide |
affects expression increases expression |
EXP ISO |
Cyclophosphamide affects the expression of GAL mRNA; Cyclophosphamide affects the expression of GAL protein Cyclophosphamide results in increased expression of GAL mRNA |
CTD |
PMID:16491427 PMID:17335920 PMID:18563302 |
|
NCBI chr 1:218,653,059...218,657,922
Ensembl chr 1:218,652,917...218,657,925
|
|
G |
Galc |
galactosylceramidase |
affects response to substance |
ISO |
GALC protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr 6:122,177,195...122,239,411
Ensembl chr 6:122,178,602...122,239,614
|
|
G |
Gamt |
guanidinoacetate N-methyltransferase |
multiple interactions |
ISO |
GAMT mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr 7:12,314,848...12,317,998
Ensembl chr 7:12,314,848...12,317,998
|
|
G |
Gap43 |
growth associated protein 43 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of GAP43 protein |
CTD |
PMID:9486479 PMID:10536274 |
|
NCBI chr11:58,624,198...58,717,916
Ensembl chr11:58,624,198...58,717,914
|
|
G |
Gas2 |
growth arrest-specific 2 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of GAS2 protein |
CTD |
PMID:17475930 |
|
NCBI chr 1:107,234,389...107,363,624
Ensembl chr 1:107,262,659...107,363,788
|
|
G |
Gata3 |
GATA binding protein 3 |
decreases expression multiple interactions |
ISO |
Cyclophosphamide results in decreased expression of GATA3 mRNA; Cyclophosphamide results in decreased expression of GATA3 protein Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of GATA3 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of GATA3 protein] |
CTD |
PMID:21041162 PMID:32151603 |
|
NCBI chr17:72,419,752...72,452,043
Ensembl chr17:72,429,618...72,450,681
|
|
G |
Gbp1 |
guanylate binding protein 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of GBP1 mRNA |
CTD |
PMID:21621594 |
|
NCBI chr 2:248,343,334...248,423,402
Ensembl chr 2:248,398,917...248,409,570
|
|
G |
Gbp4 |
guanylate binding protein 4 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of GBP3 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 2:248,249,232...248,263,104
Ensembl chr 2:248,249,468...248,263,168
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions decreases expression |
ISO |
Cyclophosphamide promotes the reaction [NFE2L2 gene mutant form results in decreased expression of GCLC protein] Cyclophosphamide results in decreased expression of GCLC mRNA; Cyclophosphamide results in decreased expression of GCLC protein |
CTD |
PMID:27633142 |
|
NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468
|
|
G |
Gdnf |
glial cell derived neurotrophic factor |
increases expression |
EXP |
Cyclophosphamide results in increased expression of GDNF mRNA |
CTD |
PMID:10683293 |
|
NCBI chr 2:56,884,181...56,912,964
Ensembl chr 2:56,887,987...56,910,238
|
|
G |
Gem |
GTP binding protein overexpressed in skeletal muscle |
increases expression |
ISO |
Cyclophosphamide results in increased expression of GEM mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 5:25,339,479...25,353,661
Ensembl chr 5:25,349,928...25,353,661
|
|
G |
Gfi1 |
growth factor independent 1 transcriptional repressor |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of GFI1 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr14:3,058,035...3,073,332
Ensembl chr14:3,058,993...3,068,371
|
|
G |
Gfra1 |
GDNF family receptor alpha 1 |
multiple interactions |
ISO |
GFRA1 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr 1:279,203,046...279,572,789
|
|
G |
Gimap4 |
GTPase, IMAP family member 4 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of GIMAP4 mRNA |
CTD |
PMID:27466211 |
|
NCBI chr 4:78,320,230...78,327,144
Ensembl chr 4:78,320,190...78,327,144
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
affects expression |
EXP |
Cyclophosphamide affects the expression of GJA1 mRNA |
CTD |
PMID:10859244 |
|
NCBI chr20:37,876,650...37,889,097
Ensembl chr20:37,876,650...37,889,089
|
|
G |
Gjb1 |
gap junction protein, beta 1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of GJB1 mRNA |
CTD |
PMID:21621594 |
|
NCBI chr X:71,272,030...71,279,973
Ensembl chr X:71,272,042...71,279,977
|
|
G |
Glis1 |
GLIS family zinc finger 1 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of GLIS1 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 5:127,043,344...127,233,395
Ensembl chr 5:127,160,495...127,233,078
|
|
G |
Glod4 |
glyoxalase domain containing 4 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of GLOD4 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr10:64,379,922...64,398,263
Ensembl chr10:64,379,921...64,398,294
|
|
G |
Glrb |
glycine receptor, beta |
increases expression |
ISO |
Cyclophosphamide results in increased expression of GLRB mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 2:179,768,040...179,842,612
Ensembl chr 2:179,769,009...179,842,547
|
|
G |
Gls |
glutaminase |
increases expression affects response to substance |
ISO |
Cyclophosphamide results in increased expression of GLS mRNA GLS protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 PMID:21527772 |
|
NCBI chr 9:54,212,622...54,284,879
Ensembl chr 9:54,212,767...54,284,872
|
|
G |
Gng12 |
G protein subunit gamma 12 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of GNG12 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 4:97,634,925...97,763,478
Ensembl chr 4:97,657,671...97,760,102
|
|
G |
Gpatch8 |
G patch domain containing 8 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of GPATCH8 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr10:90,421,443...90,501,996
Ensembl chr10:90,421,442...90,501,819
|
|
G |
Gpr137b |
G protein-coupled receptor 137B |
increases expression |
ISO |
Cyclophosphamide results in increased expression of GPR137B mRNA |
CTD |
PMID:21527772 |
|
NCBI chr17:90,670,852...90,709,003
Ensembl chr17:90,670,872...90,746,804
|
|
G |
Gpr18 |
G protein-coupled receptor 18 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of GPR18 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr15:108,323,157...108,326,907
Ensembl chr15:108,323,179...108,326,907
|
|
G |
Gpr20 |
G protein-coupled receptor 20 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of GPR20 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 7:114,943,675...114,953,977
Ensembl chr 7:114,944,282...114,945,344
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
increases expression increases activity multiple interactions |
EXP ISO |
Cyclophosphamide results in increased expression of GPT protein Cyclophosphamide results in increased activity of GPT protein Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in increased activity of GPT protein]; ganoderic acid A inhibits the reaction [Cyclophosphamide results in increased activity of GPT protein] Rutin inhibits the reaction [Cyclophosphamide results in increased activity of GPT protein]; Vitamin E inhibits the reaction [Cyclophosphamide results in increased expression of GPT protein] |
CTD |
PMID:25753322 PMID:25779342 PMID:29753871 PMID:30506662 |
|
NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
|
|
G |
Gpt2 |
glutamic--pyruvic transaminase 2 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of GPT2 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr19:22,599,003...22,633,529
Ensembl chr19:22,590,881...22,632,071
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
decreases expression multiple interactions |
ISO |
Cyclophosphamide results in decreased expression of GPX1 mRNA Plant Extracts inhibits the reaction [Cyclophosphamide results in decreased expression of GPX1 mRNA] |
CTD |
PMID:23542512 |
|
NCBI chr 8:117,117,430...117,118,528
Ensembl chr 8:117,117,430...117,118,522
|
|
G |
Gpx3 |
glutathione peroxidase 3 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of GPX3 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr10:40,247,436...40,255,423
Ensembl chr10:40,247,436...40,255,422
|
|
G |
Gpx4 |
glutathione peroxidase 4 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of GPX4 protein |
CTD |
PMID:17475930 |
|
NCBI chr 7:12,516,357...12,519,154
Ensembl chr 7:12,516,352...12,519,154
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions decreases activity |
ISO EXP |
[[Cyclophosphamide co-treated with Cisplatin co-treated with Carmustine] results in decreased activity of GSR protein] which results in increased abundance of Glutathione Disulfide; [Cyclophosphamide co-treated with Cisplatin co-treated with Carmustine] results in decreased activity of GSR protein; Buthionine Sulfoximine promotes the reaction [Cyclophosphamide results in decreased activity of GSR protein]; Plant Extracts inhibits the reaction [Buthionine Sulfoximine promotes the reaction [Cyclophosphamide results in decreased activity of GSR protein]]; Plant Extracts inhibits the reaction [Cyclophosphamide results in decreased activity of GSR protein] Plant Extracts inhibits the reaction [Cyclophosphamide results in decreased activity of GSR protein]; Rutin inhibits the reaction [Cyclophosphamide results in decreased activity of GSR protein] |
CTD |
PMID:12114195 PMID:21772021 PMID:23542512 PMID:25446862 PMID:25753322 |
|
NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
multiple interactions |
ISO |
GSTA1 protein affects the metabolism of [Cyclophosphamide metabolite co-treated with Glutathione] |
CTD |
PMID:12516103 |
|
NCBI chr 9:27,366,404...27,381,004
Ensembl chr 9:27,368,272...27,452,902
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
multiple interactions |
ISO |
[GSTM1 protein co-treated with CYP2C9 protein] results in increased susceptibility to [Busulfan co-treated with Cyclophosphamide]; GSTM1 gene affects the susceptibility to [Carmustine co-treated with Cyclophosphamide co-treated with Cisplatin] |
CTD |
PMID:16087946 PMID:28744217 |
|
NCBI chr 2:210,803,869...210,809,461
Ensembl chr 2:210,803,869...210,809,306
|
|
G |
Gstm2 |
glutathione S-transferase mu 2 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of GSTM2 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 2:210,778,041...210,782,807
Ensembl chr 2:210,720,704...210,782,856
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions decreases response to substance affects response to substance increases expression |
ISO EXP |
GSTP1 gene SNP results in increased susceptibility to [Carmustine co-treated with Doxorubicin co-treated with Cyclophosphamide co-treated with Melphalan] GSTP1 protein results in decreased susceptibility to Cyclophosphamide GSTP1 protein affects the susceptibility to Cyclophosphamide GSTP1 protein affects the reaction [Cyclophosphamide results in increased phosphorylation of MAPK8 protein]; Mesna inhibits the reaction [GSTP1 protein affects the reaction [Cyclophosphamide results in increased phosphorylation of MAPK8 protein]] Cyclophosphamide results in increased expression of GSTP1 mRNA; Cyclophosphamide results in increased expression of GSTP1 protein |
CTD |
PMID:10954901 PMID:12791655 PMID:16141653 PMID:16242832 PMID:19696094 |
|
NCBI chr 1:219,291,679...219,294,147
Ensembl chr 1:219,291,679...219,294,147
|
|
G |
Gtf2b |
general transcription factor IIB |
increases expression |
EXP |
Cyclophosphamide results in increased expression of GTF2B mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 2:248,709,433...248,727,741
Ensembl chr 2:248,715,281...248,727,741
|
|
G |
Gtf3c1 |
general transcription factor IIIC subunit 1 |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of GTF3C1 mRNA |
CTD |
PMID:16322899 |
|
NCBI chr 1:197,032,473...197,098,676
Ensembl chr 1:197,032,474...197,098,649
|
|
G |
Gusb |
glucuronidase, beta |
decreases expression increases activity multiple interactions |
EXP |
Cyclophosphamide results in decreased expression of GUSB protein Cyclophosphamide results in increased activity of GUSB protein Anthocyanins inhibits the reaction [Cyclophosphamide results in increased activity of GUSB protein]; Plant Extracts inhibits the reaction [Cyclophosphamide results in increased activity of GUSB protein] |
CTD |
PMID:17686619 PMID:25451569 |
|
NCBI chr12:30,202,066...30,215,583
Ensembl chr12:30,198,822...30,227,771
|
|
G |
Gzma |
granzyme A |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of GZMA mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 2:44,968,846...44,981,436
Ensembl chr 2:44,968,765...44,981,458
|
|
G |
Gzmb |
granzyme B |
increases expression |
ISO |
Cyclophosphamide results in increased expression of GZMB mRNA |
CTD |
PMID:15331540 |
|
NCBI chr15:35,413,862...35,417,293
Ensembl chr15:35,413,793...35,417,316
|
|
G |
H2ax |
H2A.X variant histone |
increases phosphorylation |
ISO |
Cyclophosphamide results in increased phosphorylation of H2AX protein |
CTD |
PMID:32482060 |
|
NCBI chr 8:48,665,652...48,666,981
Ensembl chr 8:48,665,652...48,666,981
|
|
G |
Hcrt |
hypocretin neuropeptide precursor |
affects localization decreases expression |
EXP |
Cyclophosphamide affects the localization of HCRT protein Cyclophosphamide results in decreased expression of HCRT mRNA |
CTD |
PMID:17881193 PMID:19666069 |
|
NCBI chr10:88,669,216...88,670,430
Ensembl chr10:88,669,214...88,670,430
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
increases expression |
ISO |
Cyclophosphamide results in increased expression of HIF1A mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
|
|
G |
Hinfp |
histone H4 transcription factor |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of HINFP mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 8:48,626,398...48,638,012
Ensembl chr 8:48,628,340...48,634,797
|
|
G |
Hm13 |
histocompatibility minor 13 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of H13 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 3:148,150,695...148,189,623
Ensembl chr 3:148,150,698...148,189,623
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
increases expression |
ISO |
Cyclophosphamide metabolite results in increased expression of HMGCS1 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 2:52,427,351...52,445,082
Ensembl chr 2:52,431,601...52,445,055
|
|
G |
Hmox1 |
heme oxygenase 1 |
affects expression decreases expression multiple interactions increases expression |
EXP ISO |
Cyclophosphamide affects the expression of HMOX1 mRNA Cyclophosphamide results in decreased expression of HMOX1 protein [astaxanthine co-treated with Cyclophosphamide] results in increased expression of HMOX1 protein; Hemin inhibits the reaction [Cyclophosphamide results in increased expression of HMOX1 mRNA]; Hemin promotes the reaction [Cyclophosphamide results in increased expression of HMOX1 mRNA]; Melatonin inhibits the reaction [Cyclophosphamide results in decreased expression of HMOX1 protein]; sacubitril-valsartan inhibits the reaction [Cyclophosphamide results in decreased expression of HMOX1 protein]; Valsartan inhibits the reaction [Cyclophosphamide results in decreased expression of HMOX1 protein] Cyclophosphamide results in increased expression of HMOX1 mRNA; Cyclophosphamide results in increased expression of HMOX1 protein |
CTD |
PMID:11906922 PMID:17979934 PMID:18206168 PMID:18246545 PMID:19952508 PMID:20038455 PMID:20433640 PMID:32197949 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hmox2 |
heme oxygenase 2 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of HMOX2 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr10:10,990,034...11,035,493
Ensembl chr10:10,990,034...11,035,484
|
|
G |
Hnrnpk |
heterogeneous nuclear ribonucleoprotein K |
increases expression |
ISO EXP |
Cyclophosphamide results in increased expression of HNRNPK protein Cyclophosphamide results in increased expression of HNRNPK mRNA |
CTD |
PMID:11599041 PMID:17475930 |
|
NCBI chr17:6,664,730...6,676,753
Ensembl chr17:6,665,659...6,676,654
|
|
G |
Hoxa1 |
homeobox A1 |
affects response to substance |
ISO |
HOXA1 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr 4:82,124,358...82,127,182
Ensembl chr 4:82,125,406...82,127,066
|
|
G |
Hprt1 |
hypoxanthine phosphoribosyltransferase 1 |
increases mutagenesis |
ISO EXP |
Cyclophosphamide results in increased mutagenesis of HPRT1 gene |
CTD |
PMID:17116724 PMID:23677247 |
|
NCBI chr X:158,196,640...158,228,815
Ensembl chr X:158,197,149...158,228,749
|
|
G |
Hsp90aa1 |
heat shock protein 90 alpha family class A member 1 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of HSP90AA1 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 6:135,107,262...135,112,793
Ensembl chr 6:135,107,271...135,112,775
|
|
G |
Hsp90ab1 |
heat shock protein 90 alpha family class B member 1 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of HSP90AB1 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 9:17,817,791...17,823,163
Ensembl chr 9:17,817,721...17,823,243
|
|
G |
Hsp90b1 |
heat shock protein 90 beta family member 1 |
decreases expression increases expression |
EXP |
Cyclophosphamide results in decreased expression of HSP90B1 mRNA Cyclophosphamide results in increased expression of HSP90B1 mRNA |
CTD |
PMID:11599041 PMID:11906922 |
|
NCBI chr 7:27,226,570...27,240,533
Ensembl chr 7:27,226,569...27,240,533
|
|
G |
Hspa1a |
heat shock protein family A (Hsp70) member 1A |
affects expression increases expression |
EXP ISO |
Cyclophosphamide affects the expression of HSPA1A mRNA Cyclophosphamide results in increased expression of HSPA1A mRNA; Cyclophosphamide results in increased expression of HSPA1A protein |
CTD |
PMID:8917683 PMID:18246545 |
|
NCBI chr20:4,875,834...4,881,751
Ensembl chr20:4,877,324...4,879,779
|
|
G |
Hspa1b |
heat shock protein family A (Hsp70) member 1B |
affects expression increases expression decreases expression |
EXP ISO |
Cyclophosphamide affects the expression of HSPA1B mRNA Cyclophosphamide metabolite results in increased expression of HSPA1B mRNA Cyclophosphamide results in decreased expression of HSPA1B mRNA |
CTD |
PMID:16141653 PMID:18246545 PMID:24356939 |
|
NCBI chr20:4,877,638...4,880,112
Ensembl chr20:2,699,712...2,701,815
|
|
G |
Hspa2 |
heat shock protein family A (Hsp70) member 2 |
affects response to substance increases expression |
ISO EXP |
HSPA2 protein affects the susceptibility to Cyclophosphamide Cyclophosphamide results in increased expression of HSPA2 mRNA |
CTD |
PMID:11599041 PMID:16217747 |
|
NCBI chr 6:99,433,575...99,436,288
Ensembl chr 6:99,433,550...99,436,289
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
decreases expression increases expression |
EXP ISO |
Cyclophosphamide results in decreased expression of HSPA5 mRNA Cyclophosphamide metabolite results in increased expression of HSPA5 mRNA |
CTD |
PMID:11906922 PMID:24356939 |
|
NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
|
|
G |
Hspa8 |
heat shock protein family A (Hsp70) member 8 |
affects response to substance |
ISO |
HSPA8 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr 8:44,989,401...44,993,261
Ensembl chr 8:44,990,014...44,993,179
|
|
G |
Hspa9 |
heat shock protein family A (Hsp70) member 9 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of HSPA9 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr18:27,731,072...27,749,235
Ensembl chr18:27,731,072...27,749,235
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
decreases expression increases expression |
EXP |
Cyclophosphamide results in decreased expression of HSPB1 mRNA Cyclophosphamide results in increased expression of HSPB1 mRNA |
CTD |
PMID:11599041 PMID:11906922 PMID:18246545 |
|
NCBI chr12:23,839,390...23,841,051
Ensembl chr12:23,839,399...23,841,049
|
|
G |
Hspd1 |
heat shock protein family D (Hsp60) member 1 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of HSPD1 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 9:61,680,529...61,691,202
Ensembl chr 9:61,680,530...61,690,956
|
|
G |
Hspe1 |
heat shock protein family E (Hsp10) member 1 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of HSPE1 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 9:61,691,246...61,724,948
Ensembl chr 9:61,692,154...61,694,599
|
|
G |
Hsph1 |
heat shock protein family H (Hsp110) member 1 |
increases expression |
ISO |
Cyclophosphamide metabolite results in increased expression of HSPH1 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr12:6,322,685...6,341,898
Ensembl chr12:6,322,668...6,341,902
|
|
G |
Hyls1 |
HYLS1, centriolar and ciliogenesis associated |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of HYLS1 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 8:36,763,470...36,772,199
Ensembl chr 8:36,763,481...36,764,422
|
|
G |
Hyou1 |
hypoxia up-regulated 1 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of HYOU1 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 8:48,699,796...48,711,912
Ensembl chr 8:48,699,769...48,711,910
|
|
G |
Ica1 |
islet cell autoantigen 1 |
affects response to substance |
ISO |
ICA1 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:11751995 |
|
NCBI chr 4:34,635,509...34,780,187
Ensembl chr 4:34,635,506...34,780,193
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
affects response to substance |
ISO |
ICAM1 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:11591119 |
|
NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
|
|
G |
Id2 |
inhibitor of DNA binding 2 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of ID2 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 6:44,360,077...44,361,908
Ensembl chr 6:44,348,501...44,363,915
|
|
G |
Idi1 |
isopentenyl-diphosphate delta isomerase 1 |
increases expression |
ISO |
Cyclophosphamide metabolite results in increased expression of IDI1 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr17:57,976,266...57,984,036
Ensembl chr17:57,976,268...57,984,036
|
|
G |
Ier3 |
immediate early response 3 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of IER3 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr20:3,438,798...3,440,002
Ensembl chr20:3,438,798...3,440,769
|
|
G |
Ier5 |
immediate early response 5 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of IER5 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr13:72,742,210...72,744,302
Ensembl chr13:72,742,210...72,744,303
|
|
G |
Ifit2 |
interferon-induced protein with tetratricopeptide repeats 2 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of IFIT2 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 1:252,894,663...252,900,727
Ensembl chr 1:252,894,663...252,900,726
|
|
G |
Ifng |
interferon gamma |
affects expression multiple interactions decreases secretion increases expression decreases expression |
ISO EXP |
Cyclophosphamide affects the expression of IFNG mRNA [Cyclophosphamide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA Cyclophosphamide results in decreased secretion of IFNG protein Cyclophosphamide results in increased expression of IFNG mRNA Cyclophosphamide results in decreased expression of IFNG mRNA Cyclophosphamide results in increased expression of IFNG protein (4-formyl-9-methoxy-5-methyl-naphtho(2,3-b)furan-3-yl)methyl acetate inhibits the reaction [Cyclophosphamide results in decreased secretion of IFNG protein]; Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of IFNG mRNA]; IFNG protein inhibits the reaction [Cyclophosphamide results in increased abundance of Nitric Oxide]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of IFNG mRNA]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased secretion of IFNG protein] |
CTD |
PMID:10607705 PMID:11006010 PMID:11014644 PMID:15331540 PMID:18848347 PMID:18957084 PMID:21068404 PMID:22842586 PMID:23395935 PMID:29594315 PMID:32151603 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Ifngr1 |
interferon gamma receptor 1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of IFNGR1 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 1:15,062,380...15,080,815
Ensembl chr 1:15,062,432...15,080,907
|
|
G |
Ifrd1 |
interferon-related developmental regulator 1 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of IFRD1 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 6:60,132,025...60,151,354
Ensembl chr 6:60,132,024...60,151,420
|
|
G |
Igf2bp3 |
insulin-like growth factor 2 mRNA binding protein 3 |
affects response to substance |
ISO |
IGF2BP3 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr 4:78,744,683...78,879,457
Ensembl chr 4:78,746,547...78,879,294
|
|
G |
Igfbp3 |
insulin-like growth factor binding protein 3 |
affects response to substance decreases expression |
ISO EXP |
IGFBP3 protein affects the susceptibility to Cyclophosphamide Cyclophosphamide results in decreased expression of IGFBP3 mRNA |
CTD |
PMID:16141653 PMID:16217747 |
|
NCBI chr14:87,457,647...87,465,374
Ensembl chr14:87,457,647...87,465,374
|
|
G |
Igfbp4 |
insulin-like growth factor binding protein 4 |
multiple interactions |
ISO |
IGFBP4 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr10:86,950,555...86,962,563
Ensembl chr10:86,950,557...86,962,578
|
|
G |
Igfbp5 |
insulin-like growth factor binding protein 5 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of IGFBP5 mRNA |
CTD |
PMID:15331540 PMID:20849824 |
|
NCBI chr 9:80,154,230...80,166,813
Ensembl chr 9:80,150,211...80,167,033
|
|
G |
Igkc |
immunoglobulin kappa constant |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of IGKC mRNA |
CTD |
PMID:15331540 |
|
|
|
G |
Il10 |
interleukin 10 |
decreases expression multiple interactions increases expression |
ISO EXP |
Cyclophosphamide results in decreased expression of IL10 mRNA [Cyclophosphamide co-treated with Methotrexate co-treated with Fluorouracil] results in decreased expression of IL10 protein Anthocyanins inhibits the reaction [Cyclophosphamide results in decreased expression of IL10 protein]; Plant Extracts inhibits the reaction [Cyclophosphamide results in decreased expression of IL10 protein] Cyclophosphamide results in increased expression of IL10 mRNA Cyclophosphamide results in increased expression of IL10 protein |
CTD |
PMID:11014644 PMID:11948286 PMID:18848347 PMID:21068404 PMID:25451569 PMID:31651976 |
|
NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
|
|
G |
Il12a |
interleukin 12A |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] results in decreased expression of [IL12A protein binds to IL12B protein] |
CTD |
PMID:29228376 |
|
NCBI chr 2:165,076,945...165,083,996
Ensembl chr 2:165,076,607...165,084,318
|
|
G |
Il12b |
interleukin 12B |
affects expression multiple interactions increases expression |
ISO |
Cyclophosphamide affects the expression of IL12B mRNA [Doxorubicin co-treated with Cyclophosphamide] results in decreased expression of [IL12A protein binds to IL12B protein] Cyclophosphamide results in increased expression of IL12B mRNA |
CTD |
PMID:15331540 PMID:18957084 PMID:22842586 PMID:29228376 |
|
NCBI chr10:30,034,447...30,048,774
Ensembl chr10:30,038,709...30,048,085
|
|
G |
Il13ra1 |
interleukin 13 receptor subunit alpha 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of IL13RA1 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr X:122,724,081...122,783,801
Ensembl chr X:122,724,129...122,781,479
|
|
G |
Il15 |
interleukin 15 |
multiple interactions decreases secretion |
ISO |
(4-formyl-9-methoxy-5-methyl-naphtho(2,3-b)furan-3-yl)methyl acetate inhibits the reaction [Cyclophosphamide results in decreased secretion of IL15 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased secretion of IL15 protein] |
CTD |
PMID:23395935 |
|
NCBI chr19:23,542,606...23,624,366
Ensembl chr19:23,542,889...23,554,594
|
|
G |
Il15ra |
interleukin 15 receptor subunit alpha |
increases expression |
ISO |
Cyclophosphamide results in increased expression of IL15RA mRNA |
CTD |
PMID:21041162 |
|
NCBI chr17:70,451,861...70,481,838
Ensembl chr17:70,451,411...70,481,750
|
|
G |
Il16 |
interleukin 16 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of IL16 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 1:145,781,923...145,881,538
Ensembl chr 1:145,781,928...145,870,912
|
|
G |
Il17a |
interleukin 17A |
decreases expression multiple interactions |
ISO |
Cyclophosphamide results in decreased expression of IL17A protein Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of IL17A protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of IL17A protein] |
CTD |
PMID:21880982 PMID:32151603 |
|
NCBI chr 9:26,841,299...26,844,786
Ensembl chr 9:26,841,299...26,844,786
|
|
G |
Il18 |
interleukin 18 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of IL18 protein |
CTD |
PMID:18848347 |
|
NCBI chr 8:55,009,666...55,016,286
Ensembl chr 8:54,993,859...55,016,299
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression multiple interactions affects response to substance |
ISO EXP |
Cyclophosphamide results in increased expression of IL1A mRNA [Cyclophosphamide co-treated with Methotrexate co-treated with Fluorouracil] results in decreased expression of IL1A protein Cyclophosphamide results in increased expression of IL1A protein IL1A promoter polymorphism affects the susceptibility to Cyclophosphamide |
CTD |
PMID:15331540 PMID:16636934 PMID:18848347 PMID:31651976 |
|
NCBI chr 3:121,824,712...121,836,122
Ensembl chr 3:121,825,412...121,836,086
|
|
G |
Il1b |
interleukin 1 beta |
increases expression decreases expression increases response to substance multiple interactions |
ISO EXP |
Cyclophosphamide results in increased expression of IL1B mRNA; Cyclophosphamide results in increased expression of IL1B protein Cyclophosphamide results in decreased expression of IL1B protein IL1B protein results in increased susceptibility to Cyclophosphamide [Cyclophosphamide co-treated with Methotrexate co-treated with Fluorouracil] results in decreased expression of IL1B protein; [Doxorubicin co-treated with Cyclophosphamide] results in decreased expression of IL1B protein; Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of IL1B protein]; Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein]; ganoderic acid A inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of IL1B protein]; VIP protein inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein] Anthocyanins inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein]; Bilirubin inhibits the reaction [Cyclophosphamide results in increased expression of IL1B mRNA]; Pentoxifylline inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein]; Plant Extracts inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein]; Rolipram inhibits the reaction [Cyclophosphamide results in increased expression of IL1B mRNA]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein] |
CTD |
PMID:8634684 PMID:11948286 PMID:15331540 PMID:18206168 PMID:18483878 PMID:18710439 PMID:18848347 PMID:20126887 PMID:23695977 PMID:25451569 PMID:29228376 PMID:29753871 PMID:30506662 PMID:31651976 PMID:32151603 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il1rn |
interleukin 1 receptor antagonist |
increases expression |
ISO |
Cyclophosphamide results in increased expression of IL1RN mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 3:1,449,778...1,468,624
Ensembl chr 3:1,452,644...1,468,614
|
|
G |
Il2 |
interleukin 2 |
increases expression decreases expression decreases secretion multiple interactions |
ISO EXP |
Cyclophosphamide results in increased expression of IL2 mRNA Cyclophosphamide results in decreased expression of IL2 mRNA Cyclophosphamide results in decreased secretion of IL2 protein (4-formyl-9-methoxy-5-methyl-naphtho(2,3-b)furan-3-yl)methyl acetate inhibits the reaction [Cyclophosphamide results in decreased secretion of IL2 protein]; Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of IL2 mRNA]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of IL2 mRNA]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased secretion of IL2 protein] Cyclophosphamide results in decreased expression of IL2 protein |
CTD |
PMID:11006010 PMID:11948286 PMID:18848347 PMID:23395935 PMID:32151603 |
|
NCBI chr 2:123,847,150...123,851,854
Ensembl chr 2:123,847,150...123,851,854
|
|
G |
Il21 |
interleukin 21 |
multiple interactions decreases expression |
ISO |
Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of IL21 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of IL21 protein] |
CTD |
PMID:32151603 |
|
NCBI chr 2:123,965,021...123,972,356
Ensembl chr 2:123,965,021...123,972,356
|
|
G |
Il23a |
interleukin 23 subunit alpha |
decreases secretion decreases expression multiple interactions |
ISO |
Cyclophosphamide results in decreased secretion of IL23A protein Cyclophosphamide results in decreased expression of IL23A protein Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of IL23A protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of IL23A protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased secretion of IL23A protein] |
CTD |
PMID:23395935 PMID:32151603 |
|
NCBI chr 7:2,710,609...2,712,723
Ensembl chr 7:2,710,609...2,712,723
|
|
G |
Il3 |
interleukin 3 |
multiple interactions |
ISO |
[Cyclophosphamide co-treated with Methotrexate co-treated with Fluorouracil] results in decreased expression of IL3 protein |
CTD |
PMID:31651976 |
|
NCBI chr10:39,620,535...39,622,973
Ensembl chr10:39,620,563...39,622,973
|
|
G |
Il4 |
interleukin 4 |
decreases expression multiple interactions increases expression |
ISO EXP |
Cyclophosphamide results in decreased expression of IL4 mRNA; Cyclophosphamide results in decreased expression of IL4 protein Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of IL4 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of IL4 protein] Cyclophosphamide results in increased expression of IL4 mRNA; Cyclophosphamide results in increased expression of IL4 protein |
CTD |
PMID:11006010 PMID:11014644 PMID:11948286 PMID:18848347 PMID:22842586 PMID:32151603 |
|
NCBI chr10:38,963,979...38,969,531
Ensembl chr10:38,963,979...38,969,531
|
|
G |
Il5 |
interleukin 5 |
increases expression |
ISO EXP |
Cyclophosphamide results in increased expression of IL5 mRNA; Cyclophosphamide results in increased expression of IL5 protein |
CTD |
PMID:11006010 PMID:18848347 |
|
NCBI chr10:39,066,716...39,069,587
Ensembl chr10:39,066,716...39,069,587
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases expression decreases secretion |
ISO EXP |
[Doxorubicin co-treated with Cyclophosphamide] results in decreased expression of IL6 protein; ganoderic acid A inhibits the reaction [Cyclophosphamide results in increased expression of IL6 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased secretion of IL6 protein]; Sizofiran promotes the reaction [Cyclophosphamide results in increased expression of IL6 mRNA]; Sizofiran promotes the reaction [Cyclophosphamide results in increased expression of IL6 protein] Cyclophosphamide results in increased expression of IL6 mRNA; Cyclophosphamide results in increased expression of IL6 protein Pentoxifylline inhibits the reaction [Cyclophosphamide results in increased expression of IL6 protein]; Rutin inhibits the reaction [Cyclophosphamide results in increased expression of IL6 protein]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of IL6 protein] |
CTD |
PMID:10052129 PMID:11948286 PMID:17010015 PMID:18848347 PMID:20126887 PMID:21068404 PMID:22842586 PMID:23395935 PMID:23695977 PMID:25753322 PMID:29228376 PMID:30506662 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Ilf3 |
interleukin enhancer binding factor 3 |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of ILF3 mRNA |
CTD |
PMID:16322899 |
|
NCBI chr 8:22,402,877...22,440,984
Ensembl chr 8:22,402,890...22,440,885
|
|
G |
Irag2 |
inositol 1,4,5-triphosphate receptor associated 2 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of LRMP mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 4:179,402,929...179,440,792
Ensembl chr 4:179,398,621...179,440,792
|
|
G |
Irs1 |
insulin receptor substrate 1 |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of IRS1 mRNA |
CTD |
PMID:16322899 |
|
NCBI chr 9:88,033,668...88,086,488
Ensembl chr 9:88,033,668...88,086,488
|
|
G |
Isg15 |
ISG15 ubiquitin-like modifier |
increases expression |
ISO |
Cyclophosphamide results in increased expression of ISG15 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 5:173,624,862...173,629,124
Ensembl chr 5:173,624,310...173,626,248
|
|
G |
Isl2 |
ISL LIM homeobox 2 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of ISL2 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 8:60,117,565...60,122,716
Ensembl chr 8:60,117,729...60,122,211
|
|
G |
Itk |
IL2-inducible T-cell kinase |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of ITK mRNA |
CTD |
PMID:21041162 |
|
NCBI chr10:31,431,820...31,493,413
Ensembl chr10:31,431,809...31,493,419
|
|
G |
Jchain |
joining chain of multimeric IgA and IgM |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of JCHAIN mRNA |
CTD |
PMID:15331540 |
|
NCBI chr14:21,176,841...21,183,731
Ensembl chr14:21,177,237...21,183,542
|
|
G |
Kbtbd11 |
kelch repeat and BTB domain containing 11 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of KBTBD11 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr16:79,696,395...79,716,129
Ensembl chr16:79,696,891...79,700,992
|
|
G |
Kcnq4 |
potassium voltage-gated channel subfamily Q member 4 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of KCNQ4 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 5:139,625,783...139,677,300
Ensembl chr 5:139,627,576...139,677,300
|
|
G |
Kdm1a |
lysine demethylase 1A |
multiple interactions increases expression |
ISO |
Cyclophosphamide promotes the reaction [KDM1A protein results in decreased methylation of and results in decreased degradation of DNMT1 protein] Cyclophosphamide results in increased expression of KDM1A protein |
CTD |
PMID:22007908 |
|
NCBI chr 5:154,909,003...154,965,171
Ensembl chr 5:154,909,003...154,965,171
|
|
G |
Kdm2a |
lysine demethylase 2A |
increases expression |
EXP |
Cyclophosphamide results in increased expression of KDM2A mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 1:219,566,130...219,642,294
Ensembl chr 1:219,566,156...219,640,294
|
|
G |
Kdm4b |
lysine demethylase 4B |
multiple interactions |
ISO |
KDM4B mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr 9:10,656,035...10,734,127
Ensembl chr 9:10,653,216...10,734,073
|
|
G |
Kdr |
kinase insert domain receptor |
decreases expression increases expression |
EXP |
Cyclophosphamide results in decreased expression of KDR mRNA; Cyclophosphamide results in decreased expression of KDR protein Cyclophosphamide results in increased expression of KDR mRNA |
CTD |
PMID:18632792 PMID:19701751 |
|
NCBI chr14:34,727,677...34,787,127
Ensembl chr14:34,727,623...34,787,183
|
|
G |
Kif21b |
kinesin family member 21B |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of KIF21B mRNA |
CTD |
PMID:24356939 |
|
NCBI chr13:52,976,505...53,026,750
Ensembl chr13:52,976,507...53,023,103
|
|
G |
Kif3a |
kinesin family member 3a |
multiple interactions |
ISO |
KIF3A mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr10:38,918,705...38,953,958
Ensembl chr10:38,918,748...38,952,785
|
|
G |
Kitlg |
KIT ligand |
affects expression increases expression multiple interactions |
ISO |
Cyclophosphamide affects the expression of KITL mRNA Cyclophosphamide results in increased expression of KITL mRNA [Cyclophosphamide co-treated with Sizofiran] results in increased expression of KITL mRNA |
CTD |
PMID:10052129 PMID:12624490 PMID:12662436 |
|
NCBI chr 7:42,269,784...42,351,054
Ensembl chr 7:42,269,784...42,351,054
|
|
G |
Klf13 |
Kruppel-like factor 13 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of KLF13 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 1:124,772,596...124,803,363
Ensembl chr 1:124,772,596...124,803,363
|
|
G |
Klf2 |
Kruppel-like factor 2 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of KLF2 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr16:19,223,087...19,225,037
Ensembl chr16:19,223,087...19,225,037
|
|
G |
Klf4 |
Kruppel like factor 4 |
decreases response to substance |
ISO |
KLF4 results in decreased susceptibility to Cyclophosphamide |
CTD |
PMID:21833590 |
|
NCBI chr 5:72,283,311...72,287,669
Ensembl chr 5:72,283,313...72,287,669
|
|
G |
Klf5 |
Kruppel-like factor 5 |
affects response to substance |
ISO |
KLF5 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr15:83,703,796...83,722,921
Ensembl chr15:83,703,791...83,722,921
|
|
G |
Krcc1 |
lysine-rich coiled-coil 1 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of KRCC1 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 4:99,133,735...99,148,236
Ensembl chr 4:99,133,842...99,146,827
|
|
G |
Krt8 |
keratin 8 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of KRT8 mRNA |
CTD |
PMID:21621594 |
|
NCBI chr 7:143,596,511...143,603,745
Ensembl chr 7:143,596,511...143,603,803
|
|
G |
Krt80 |
keratin 80 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of KRT80 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 7:142,995,715...143,015,932
Ensembl chr 7:142,994,119...143,016,040
|
|
G |
Lama5 |
laminin subunit alpha 5 |
increases expression multiple interactions |
ISO |
Cyclophosphamide results in increased expression of LAMA5 mRNA 5-(N-methyl-N-propargylaminomethyl)-8-hydroxyquinoline inhibits the reaction [Cyclophosphamide results in increased expression of LAMA5 mRNA] |
CTD |
PMID:30760223 |
|
NCBI chr 3:175,553,042...175,601,112
Ensembl chr 3:175,553,045...175,601,127
|
|
G |
Lamc2 |
laminin subunit gamma 2 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of LAMC2 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr13:70,566,643...70,632,126
Ensembl chr13:70,566,643...70,626,252
|
|
G |
Lasp1 |
LIM and SH3 protein 1 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of LASP1 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr10:85,744,662...85,785,130
Ensembl chr10:85,744,568...85,785,133
|
|
G |
Lat |
linker for activation of T cells |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of LAT mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 1:197,765,644...197,770,669
Ensembl chr 1:197,765,644...197,770,669
|
|
G |
Lck |
LCK proto-oncogene, Src family tyrosine kinase |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of LCK mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 5:147,750,976...147,779,627
Ensembl chr 5:147,750,973...147,761,983
|
|
G |
Lcn2 |
lipocalin 2 |
increases expression multiple interactions |
ISO EXP |
Cyclophosphamide results in increased expression of LCN2 mRNA [Cyclophosphamide co-treated with Mecamylamine] results in increased expression of LCN2 mRNA |
CTD |
PMID:15331540 PMID:18433785 PMID:20623750 |
|
NCBI chr 3:11,414,189...11,417,534
Ensembl chr 3:11,414,186...11,417,546
|
|
G |
Ldhb |
lactate dehydrogenase B |
affects response to substance |
ISO |
LDHB protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr 4:176,701,980...176,719,999
Ensembl chr 4:176,701,983...176,720,012
|
|
G |
Lef1 |
lymphoid enhancer binding factor 1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of LEF1 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 2:236,232,115...236,345,061
Ensembl chr 2:236,233,239...236,345,056
|
|
G |
Lgals1 |
galectin 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of LGALS1 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 7:120,153,184...120,156,290
Ensembl chr 7:120,153,184...120,156,289
|
|
G |
Lgals7 |
galectin 7 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of LGALS7 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 1:87,044,823...87,047,223
Ensembl chr 1:87,045,335...87,047,223
|
|
G |
Lhb |
luteinizing hormone subunit beta |
decreases secretion multiple interactions |
EXP |
Cyclophosphamide results in decreased secretion of LHB protein sacubitril-valsartan inhibits the reaction [Cyclophosphamide results in decreased secretion of LHB protein]; Valsartan inhibits the reaction [Cyclophosphamide results in decreased secretion of LHB protein] |
CTD |
PMID:25446862 PMID:32197949 |
|
NCBI chr 1:101,409,992...101,413,725
Ensembl chr 1:101,410,019...101,413,724
|
|
G |
Lhx2 |
LIM homeobox 2 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of LHX2 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 3:22,628,674...22,658,447
Ensembl chr 3:22,640,545...22,658,446
|
|
G |
Limd1 |
LIM domains containing 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of LIMD1 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 8:132,553,218...132,598,826
Ensembl chr 8:132,553,218...132,598,812
|
|
G |
Lmcd1 |
LIM and cysteine-rich domains 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of LMCD1 mRNA |
CTD |
PMID:23558518 |
|
NCBI chr 4:144,192,989...144,252,554
Ensembl chr 4:144,192,989...144,252,551
|
|
G |
Lmnb1 |
lamin B1 |
multiple interactions |
ISO |
[Cladribine co-treated with Cyclophosphamide co-treated with Mitoxantrone] results in decreased expression of LMNB1 protein; [Cladribine co-treated with Cyclophosphamide] results in decreased expression of LMNB1 protein |
CTD |
PMID:15582267 |
|
NCBI chr18:51,785,111...51,822,264
Ensembl chr18:51,785,111...51,822,264
|
|
G |
Lonrf2 |
LON peptidase N-terminal domain and ring finger 2 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of LONRF2 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 9:45,468,001...45,506,448
Ensembl chr 9:45,466,688...45,505,767
|
|
G |
Lsg1 |
large 60S subunit nuclear export GTPase 1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of LSG1 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr11:73,693,862...73,723,457
Ensembl chr11:73,693,814...73,723,501
|
|
G |
Ltbr |
lymphotoxin beta receptor |
increases expression |
ISO |
Cyclophosphamide results in increased expression of LTBR mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 4:157,822,838...157,829,291
Ensembl chr 4:157,822,840...157,829,241
|
|
G |
Ltf |
lactotransferrin |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of LTF mRNA |
CTD |
PMID:21621594 |
|
NCBI chr 8:119,290,416...119,313,261
Ensembl chr 8:119,290,416...119,313,261
|
|
G |
Maged1 |
MAGE family member D1 |
affects response to substance |
ISO |
MAGED1 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr X:63,803,194...63,809,715
Ensembl chr X:63,803,189...63,809,861
|
|
G |
Man2b2 |
mannosidase, alpha, class 2B, member 2 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of MAN2B2 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr14:78,939,959...78,964,961
Ensembl chr14:78,939,903...78,964,961
|
|
G |
Maoa |
monoamine oxidase A |
increases expression |
ISO |
Cyclophosphamide results in increased expression of MAOA mRNA |
CTD |
PMID:17403535 |
|
NCBI chr X:6,554,698...6,620,722
Ensembl chr X:6,554,698...6,620,722
|
|
G |
Map3k12 |
mitogen activated protein kinase kinase kinase 12 |
affects expression |
EXP |
Cyclophosphamide affects the expression of MAP3K12 mRNA |
CTD |
PMID:18246545 |
|
NCBI chr 7:144,102,275...144,120,306
Ensembl chr 7:144,102,680...144,109,116
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation multiple interactions increases expression |
ISO EXP |
Cyclophosphamide results in increased phosphorylation of MAPK1 protein Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; NGF protein affects the reaction [Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK1 protein] Cyclophosphamide results in increased expression of MAPK1 mRNA; Cyclophosphamide results in increased expression of MAPK1 protein modified form |
CTD |
PMID:11599041 PMID:15733095 PMID:17110531 PMID:17409261 PMID:19638304 PMID:19696094 PMID:19996110 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions decreases expression affects expression |
ISO EXP |
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of MAPK14 mRNA Cyclophosphamide results in decreased expression of MAPK14 mRNA Cyclophosphamide affects the expression of MAPK14 mRNA |
CTD |
PMID:16322899 PMID:18246545 |
|
NCBI chr20:5,933,290...5,995,137
Ensembl chr20:5,933,303...5,995,137
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases expression multiple interactions increases phosphorylation |
EXP ISO |
Cyclophosphamide results in increased expression of MAPK3 protein modified form Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; NGF protein affects the reaction [Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK3 protein] Cyclophosphamide results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:15733095 PMID:17110531 PMID:17409261 PMID:19638304 PMID:19696094 PMID:19996110 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mapk7 |
mitogen-activated protein kinase 7 |
multiple interactions |
EXP |
Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK7 protein |
CTD |
PMID:17110531 |
|
NCBI chr10:47,768,592...47,775,130
Ensembl chr10:47,766,680...47,775,055
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
increases phosphorylation multiple interactions |
ISO EXP |
Cyclophosphamide results in increased phosphorylation of MAPK8 protein Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK8 protein; NGF protein affects the reaction [Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK8 protein] GSTP1 protein affects the reaction [Cyclophosphamide results in increased phosphorylation of MAPK8 protein]; GSTP2 protein affects the reaction [Cyclophosphamide results in increased phosphorylation of MAPK8 protein]; Mesna inhibits the reaction [Cyclophosphamide results in increased phosphorylation of MAPK8 protein]; Mesna inhibits the reaction [GSTP1 protein affects the reaction [Cyclophosphamide results in increased phosphorylation of MAPK8 protein]]; Mesna inhibits the reaction [GSTP2 protein affects the reaction [Cyclophosphamide results in increased phosphorylation of MAPK8 protein]] |
CTD |
PMID:19696094 PMID:19996110 |
|
NCBI chr16:9,620,854...9,709,342
Ensembl chr16:9,625,177...9,709,347
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions |
EXP |
Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK9 protein; NGF protein affects the reaction [Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK9 protein] |
CTD |
PMID:19996110 |
|
NCBI chr10:35,333,859...35,374,364
Ensembl chr10:35,333,859...35,374,355
|
|
G |
Mapt |
microtubule-associated protein tau |
multiple interactions |
ISO |
MAPT mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr10:92,289,002...92,386,517
Ensembl chr10:92,288,910...92,386,517
|
|
G |
Marchf7 |
membrane associated ring-CH-type finger 7 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of MARCHF7 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 3:46,284,961...46,325,230
Ensembl chr 3:46,286,712...46,324,057
|
|
G |
Marcks |
myristoylated alanine rich protein kinase C substrate |
increases expression |
ISO |
Cyclophosphamide results in increased expression of MARCKS mRNA |
CTD |
PMID:17403535 |
|
NCBI chr20:42,966,140...42,971,838
Ensembl chr20:42,966,140...42,971,838
|
|
G |
Mcm5 |
minichromosome maintenance complex component 5 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of MCM5 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr19:14,523,482...14,561,281
Ensembl chr19:14,523,554...14,561,278
|
|
G |
Mdfic |
MyoD family inhibitor domain containing |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of MDFIC mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 4:42,202,546...42,282,499
Ensembl chr 4:42,202,838...42,282,496
|
|
G |
Med13l |
mediator complex subunit 13L |
multiple interactions |
ISO |
MED13L mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr12:43,421,317...43,576,859
Ensembl chr12:43,421,308...43,576,804
|
|
G |
Melk |
maternal embryonic leucine zipper kinase |
multiple interactions |
ISO |
MELK mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr 5:59,783,835...59,844,356
Ensembl chr 5:59,783,890...59,844,356
|
|
G |
Metrn |
meteorin, glial cell differentiation regulator |
multiple interactions |
ISO |
METRN mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr10:15,164,439...15,166,457
Ensembl chr10:15,164,439...15,166,457
|
|
G |
Mfge8 |
milk fat globule EGF and factor V/VIII domain containing |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of MFGE8 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 1:140,845,478...140,860,882
Ensembl chr 1:140,845,465...140,860,894
|
|
G |
Mgmt |
O-6-methylguanine-DNA methyltransferase |
decreases expression decreases response to substance |
ISO |
Cyclophosphamide results in decreased expression of MGMT mRNA MGMT protein results in decreased susceptibility to Cyclophosphamide |
CTD |
PMID:15741301 PMID:17403535 |
|
NCBI chr 1:209,237,255...209,464,189
Ensembl chr 1:209,237,233...209,464,190
|
|
G |
Mgst1 |
microsomal glutathione S-transferase 1 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of MGST1 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 4:172,119,382...172,134,609
Ensembl chr 4:172,119,331...172,134,607
|
|
G |
Mif |
macrophage migration inhibitory factor |
multiple interactions |
EXP |
Cyclophosphamide affects the localization of and affects the expression of MIF protein; Cyclophosphamide promotes the reaction [MIF protein binds to CXCR4 protein] |
CTD |
PMID:19066630 |
|
NCBI chr20:13,715,219...13,732,980
Ensembl chr20:13,732,198...13,732,859
|
|
G |
Mlh1 |
mutL homolog 1 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of MLH1 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 8:119,486,655...119,523,716
Ensembl chr 8:119,486,691...119,523,964
|
|
G |
Mmel1 |
membrane metallo-endopeptidase-like 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of MMEL1 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 5:172,273,450...172,303,905
Ensembl chr 5:172,273,459...172,304,225
|
|
G |
Mmp11 |
matrix metallopeptidase 11 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of MMP11 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr20:13,670,051...13,678,834
Ensembl chr20:13,670,066...13,678,089
|
|
G |
Mmp3 |
matrix metallopeptidase 3 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of MMP3 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 8:5,676,608...5,698,579
Ensembl chr 8:5,676,665...5,698,579
|
|
G |
Mmp8 |
matrix metallopeptidase 8 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of MMP8 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 8:5,768,808...5,777,741
Ensembl chr 8:5,768,811...5,778,702
|
|
G |
Mnda |
myeloid cell nuclear differentiation antigen |
increases expression |
ISO |
Cyclophosphamide results in increased expression of IFI204 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr13:92,073,664...92,091,335
Ensembl chr13:92,073,668...92,089,980
|
|
G |
Mpc2 |
mitochondrial pyruvate carrier 2 |
affects response to substance |
ISO |
MPC2 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr13:83,680,527...83,700,491
Ensembl chr13:83,681,322...83,700,213
|
|
G |
Mpg |
N-methylpurine-DNA glycosylase |
affects expression |
EXP |
Cyclophosphamide affects the expression of MPG mRNA |
CTD |
PMID:11906922 |
|
NCBI chr10:15,661,768...15,667,995
Ensembl chr10:15,661,608...15,668,022
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions increases activity |
EXP |
Anthocyanins inhibits the reaction [Cyclophosphamide results in increased activity of MPO protein]; Hemin inhibits the reaction [Cyclophosphamide results in increased activity of MPO protein]; Plant Extracts inhibits the reaction [Cyclophosphamide results in increased activity of MPO protein]; Rolipram inhibits the reaction [Cyclophosphamide results in increased activity of MPO protein] |
CTD |
PMID:10749792 PMID:17979934 PMID:18710439 PMID:25451569 |
|
NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
|
|
G |
Mr1 |
major histocompatibility complex, class I-related |
increases expression |
ISO |
Cyclophosphamide results in increased expression of MR1 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr13:72,771,992...72,789,861
Ensembl chr13:72,771,984...72,789,841
|
|
G |
Ms4a3 |
membrane spanning 4-domains A3 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of MS4A3 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 1:227,979,307...227,994,210
Ensembl chr 1:227,979,481...227,992,623
|
|
G |
Msh2 |
mutS homolog 2 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of MSH2 mRNA |
CTD |
PMID:11056294 PMID:11906922 |
|
NCBI chr 6:11,215,951...11,274,916
Ensembl chr 6:11,215,963...11,274,932
|
|
G |
Msh3 |
mutS homolog 3 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of MSH3 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 2:21,790,048...21,931,791
Ensembl chr 2:21,790,044...21,931,720
|
|
G |
Mss51 |
MSS51 mitochondrial translational activator |
increases expression |
EXP |
Cyclophosphamide results in increased expression of MSS51 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr15:4,240,203...4,252,072
Ensembl chr15:4,240,203...4,252,072
|
|
G |
Mthfd2 |
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of MTHFD2 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 4:115,004,433...115,015,965
Ensembl chr 4:115,004,448...115,015,965
|
|
G |
Mtr |
5-methyltetrahydrofolate-homocysteine methyltransferase |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of MTR mRNA |
CTD |
PMID:27281708 |
|
NCBI chr17:66,210,444...66,295,014
Ensembl chr17:66,210,461...66,295,014
|
|
G |
Muc13 |
mucin 13, cell surface associated |
increases expression |
ISO |
Cyclophosphamide results in increased expression of MUC13 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr11:70,185,757...70,223,012
Ensembl chr11:70,185,757...70,211,701
|
|
G |
Mxi1 |
MAX interactor 1, dimerization protein |
affects response to substance |
ISO |
MXI1 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr 1:274,030,748...274,090,071
Ensembl chr 1:274,030,978...274,090,071
|
|
G |
Myh10 |
myosin heavy chain 10 |
affects response to substance |
ISO |
MYH10 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr10:55,274,910...55,406,738
Ensembl chr10:55,275,411...55,406,732
|
|
G |
Naip6 |
NLR family, apoptosis inhibitory protein 6 |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of NAIP mRNA |
CTD |
PMID:16322899 |
|
NCBI chr 2:30,377,505...30,418,578
|
|
G |
Nampt |
nicotinamide phosphoribosyltransferase |
increases expression |
ISO |
Cyclophosphamide results in increased expression of NAMPT mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 6:52,122,085...52,156,473
Ensembl chr 6:52,122,085...52,156,472
|
|
G |
Nanos1 |
nanos C2HC-type zinc finger 1 |
increases expression |
ISO |
Cyclophosphamide metabolite results in increased expression of NANOS1 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 1:282,134,676...282,140,370
Ensembl chr 1:282,134,981...282,135,772
|
|
G |
Nasp |
nuclear autoantigenic sperm protein |
increases expression |
EXP |
Cyclophosphamide results in increased expression of NASP mRNA |
CTD |
PMID:16141653 |
|
NCBI chr 5:135,446,485...135,472,113
Ensembl chr 5:135,446,962...135,472,116
|
|
G |
Ncoa7 |
nuclear receptor coactivator 7 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of NCOA7 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 1:29,225,727...29,386,642
Ensembl chr 1:29,225,707...29,385,199
|
|
G |
Ndufs2 |
NADH:ubiquinone oxidoreductase core subunit S2 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of NDUFS2 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr13:89,606,848...89,623,506
Ensembl chr13:89,606,840...89,619,398
|
|
G |
Neto2 |
neuropilin and tolloid like 2 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of NETO2 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr19:22,450,579...22,486,530
Ensembl chr19:22,450,030...22,486,531
|
|
G |
Nfatc3 |
nuclear factor of activated T-cells 3 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of NFATC3 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr19:38,039,542...38,114,003
Ensembl chr19:38,039,564...38,114,003
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
multiple interactions increases response to substance increases expression decreases expression |
EXP ISO |
[astaxanthine co-treated with Cyclophosphamide] results in increased expression of NFE2L2 protein; Melatonin inhibits the reaction [Cyclophosphamide results in decreased expression of NFE2L2 protein] Cyclophosphamide promotes the reaction [NFE2L2 gene mutant form results in decreased expression of CAT protein]; Cyclophosphamide promotes the reaction [NFE2L2 gene mutant form results in decreased expression of GCLC protein]; Cyclophosphamide promotes the reaction [NFE2L2 gene mutant form results in decreased expression of NQO1 protein]; NFE2L2 gene mutant form inhibits the reaction [Cyclophosphamide results in increased expression of NQO1 mRNA]; NFE2L2 gene mutant form promotes the reaction [Cyclophosphamide results in decreased expression of CAT protein]; NFE2L2 gene mutant form promotes the reaction [Cyclophosphamide results in decreased expression of NQO1 protein] NFE2L2 gene mutant form results in increased susceptibility to Cyclophosphamide Cyclophosphamide results in increased expression of NFE2L2 protein |
CTD |
PMID:20038455 PMID:20433640 PMID:27633142 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nfe2l3 |
nuclear factor, erythroid 2-like 3 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of NFE2L3 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 4:81,205,214...81,233,068
Ensembl chr 4:81,205,404...81,232,813
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
increases phosphorylation multiple interactions |
ISO |
Cyclophosphamide results in increased phosphorylation of NFKBIA protein ganoderic acid A inhibits the reaction [Cyclophosphamide results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:30506662 |
|
NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
|
|
G |
Nfkbiz |
NFKB inhibitor zeta |
increases expression |
ISO |
Cyclophosphamide results in increased expression of NFKBIZ mRNA |
CTD |
PMID:15331540 |
|
NCBI chr11:47,243,342...47,271,487
Ensembl chr11:47,243,342...47,271,487
|
|
G |
Ngf |
nerve growth factor |
multiple interactions increases expression decreases expression |
ISO EXP |
3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazoleacetic acid methyl ester inhibits the reaction [Cyclophosphamide results in increased expression of NGF protein]; Cyclophosphamide promotes the reaction [NGF results in increased expression of VEGFA mRNA]; VIP protein affects the reaction [Cyclophosphamide results in increased expression of NGF protein] Cyclophosphamide results in decreased expression of NGF protein Cyclophosphamide results in increased expression of NGF mRNA; Cyclophosphamide results in increased expression of NGF protein NGF protein affects the reaction [Cyclophosphamide results in increased phosphorylation of and results in increased activity of AKT1 protein]; NGF protein affects the reaction [Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; NGF protein affects the reaction [Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; NGF protein affects the reaction [Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK8 protein]; NGF protein affects the reaction [Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK9 protein]; rofecoxib inhibits the reaction [Cyclophosphamide results in increased expression of NGF protein] |
CTD |
PMID:10683293 PMID:16879691 PMID:18299998 PMID:18632792 PMID:19996110 PMID:20127836 |
|
NCBI chr 2:204,886,158...204,939,523
Ensembl chr 2:204,886,202...204,940,453
|
|
G |
Ngfr |
nerve growth factor receptor |
increases expression |
EXP |
Cyclophosphamide results in increased expression of NGFR mRNA; Cyclophosphamide results in increased expression of NGFR protein |
CTD |
PMID:8817519 PMID:18189308 PMID:18842820 |
|
NCBI chr10:83,389,828...83,408,061
Ensembl chr10:83,389,847...83,408,061
|
|
G |
Nid1 |
nidogen 1 |
affects response to substance |
ISO |
NID1 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr17:90,553,161...90,627,133
Ensembl chr17:90,553,394...90,627,101
|
|
G |
Nkain1 |
Sodium/potassium transporting ATPase interacting 1 |
multiple interactions |
ISO |
NKAIN1 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr 5:148,635,537...148,669,709
Ensembl chr 5:148,661,070...148,667,746
|
|
G |
Nme1 |
NME/NM23 nucleoside diphosphate kinase 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of NME1 mRNA |
CTD |
PMID:11599041 |
|
NCBI chr10:81,657,152...81,666,542
Ensembl chr10:81,657,153...81,666,523
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions increases expression increases activity |
EXP ISO |
Bilirubin inhibits the reaction [Cyclophosphamide results in increased expression of NOS2 mRNA]; Bilirubin inhibits the reaction [Cyclophosphamide results in increased expression of NOS2 protein]; ginkgolide B inhibits the reaction [Cyclophosphamide results in increased activity of NOS2 protein]; N-((3-(aminomethyl)phenyl)methyl)ethanimidamide inhibits the reaction [Cyclophosphamide results in increased activity of NOS2 protein]; pimagedine inhibits the reaction [Cyclophosphamide results in increased activity of NOS2 protein]; rofecoxib inhibits the reaction [Cyclophosphamide results in increased expression of NOS2 protein]; Rolipram inhibits the reaction [Cyclophosphamide results in increased expression of NOS2 mRNA]; Rolipram inhibits the reaction [Cyclophosphamide results in increased expression of NOS2 protein]; Rutin inhibits the reaction [Cyclophosphamide results in increased expression of NOS2 protein]; sacubitril-valsartan inhibits the reaction [Cyclophosphamide results in increased expression of NOS2 protein]; Valsartan inhibits the reaction [Cyclophosphamide results in increased expression of NOS2 protein] Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in increased expression of NOS2 protein] Cyclophosphamide results in increased expression of NOS2 mRNA; Cyclophosphamide results in increased expression of NOS2 protein |
CTD |
PMID:9006340 PMID:10607705 PMID:11046124 PMID:15821589 PMID:16879691 PMID:18206168 PMID:18296739 PMID:18710439 PMID:19691848 PMID:21068404 PMID:25753322 PMID:29753871 PMID:32197949 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Nos3 |
nitric oxide synthase 3 |
decreases activity increases expression |
EXP |
Cyclophosphamide results in decreased activity of NOS3 protein Cyclophosphamide results in increased expression of NOS3 protein |
CTD |
PMID:9006340 PMID:16125470 |
|
NCBI chr 4:7,321,908...7,342,404
Ensembl chr 4:7,320,668...7,342,410
|
|
G |
Nppb |
natriuretic peptide B |
increases expression |
ISO |
Cyclophosphamide results in increased expression of NPPB protein |
CTD |
PMID:17562616 PMID:18548196 PMID:18999883 |
|
NCBI chr 5:164,796,176...164,797,538
Ensembl chr 5:164,796,185...164,797,531
|
|
G |
Nprl2 |
NPR2-like, GATOR1 complex subunit |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of NPRL2 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 8:116,297,950...116,301,123
Ensembl chr 8:116,297,950...116,301,122
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
decreases expression multiple interactions increases expression |
EXP ISO |
Cyclophosphamide results in decreased expression of NQO1 mRNA; Cyclophosphamide results in decreased expression of NQO1 protein Cyclophosphamide promotes the reaction [NFE2L2 gene mutant form results in decreased expression of NQO1 protein]; NFE2L2 gene mutant form inhibits the reaction [Cyclophosphamide results in increased expression of NQO1 mRNA]; NFE2L2 gene mutant form promotes the reaction [Cyclophosphamide results in decreased expression of NQO1 protein] Cyclophosphamide results in increased expression of NQO1 protein [astaxanthine co-treated with Cyclophosphamide] results in increased expression of NQO1 protein; Melatonin inhibits the reaction [Cyclophosphamide results in decreased expression of NQO1 protein]; sacubitril-valsartan inhibits the reaction [Cyclophosphamide results in decreased expression of NQO1 protein]; Valsartan inhibits the reaction [Cyclophosphamide results in decreased expression of NQO1 protein] |
CTD |
PMID:11906922 PMID:20038455 PMID:20433640 PMID:21041162 PMID:27633142 PMID:32197949 |
|
NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of NR1H4 mRNA |
CTD |
PMID:28391356 |
|
NCBI chr 7:30,003,429...30,162,095
Ensembl chr 7:30,003,429...30,162,056
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity multiple interactions |
ISO |
Cyclophosphamide results in increased activity of NR1I2 protein [Cyclophosphamide results in increased activity of NR1I2 protein] which results in increased expression of ABCB1 mRNA; [Cyclophosphamide results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; Cyclophosphamide binds to and results in increased activity of NR1I2 protein; NR1I2 protein promotes the reaction [Cyclophosphamide results in increased expression of ABCB1 protein] |
CTD |
PMID:17041008 PMID:18839173 PMID:20041327 |
|
NCBI chr11:65,022,100...65,058,546
Ensembl chr11:65,022,100...65,058,545
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
multiple interactions |
ISO |
[Cyclophosphamide results in increased activity of NR1I3 protein alternative form] which results in increased expression of CYP2B6 mRNA |
CTD |
PMID:17041008 |
|
NCBI chr13:89,585,072...89,591,278
Ensembl chr13:89,586,283...89,591,277
|
|
G |
Nr2c2 |
nuclear receptor subfamily 2, group C, member 2 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of NR2C2 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 4:124,005,287...124,030,349
Ensembl chr 4:124,005,280...124,030,349
|
|
G |
Nrap |
nebulin-related anchoring protein |
increases expression |
EXP |
Cyclophosphamide results in increased expression of NRAP mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 1:277,104,519...277,181,397
Ensembl chr 1:277,104,514...277,181,414
|
|
G |
Nrdc |
nardilysin convertase |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of NRD1 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 5:128,629,949...128,694,209
Ensembl chr 5:128,629,942...128,694,060
|
|
G |
Nrg1 |
neuregulin 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of NRG1 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr16:62,969,573...64,065,063
Ensembl chr16:63,837,216...64,057,434
|
|
G |
Nrp1 |
neuropilin 1 |
decreases expression increases expression |
ISO EXP |
Cyclophosphamide results in decreased expression of NRP1 mRNA Cyclophosphamide results in increased expression of NRP1 mRNA |
CTD |
PMID:15331540 PMID:18632792 |
|
NCBI chr19:61,332,351...61,486,166
Ensembl chr19:61,332,351...61,485,858
|
|
G |
Nrp2 |
neuropilin 2 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of NRP2 mRNA |
CTD |
PMID:18632792 |
|
NCBI chr 9:69,496,875...69,609,802
Ensembl chr 9:69,497,121...69,612,087
|
|
G |
Nt5c2 |
5'-nucleotidase, cytosolic II |
increases expression |
ISO |
Cyclophosphamide results in increased expression of NT5C2 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 1:266,652,966...266,782,935
Ensembl chr 1:266,659,519...266,782,910
|
|
G |
Ntf3 |
neurotrophin 3 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of NTF3 mRNA |
CTD |
PMID:10683293 |
|
NCBI chr 4:158,636,883...158,705,886
Ensembl chr 4:158,636,884...158,705,886
|
|
G |
Ntf4 |
neurotrophin 4 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of NTF4 mRNA |
CTD |
PMID:10683293 |
|
NCBI chr 1:101,405,314...101,408,145
Ensembl chr 1:101,405,314...101,408,145
|
|
G |
Ntrk1 |
neurotrophic receptor tyrosine kinase 1 |
multiple interactions |
EXP |
Cyclophosphamide results in increased phosphorylation of and results in increased expression of NTRK1 protein |
CTD |
PMID:12412144 |
|
NCBI chr 2:187,143,568...187,160,373
Ensembl chr 2:187,143,568...187,160,373
|
|
G |
Ntrk2 |
neurotrophic receptor tyrosine kinase 2 |
multiple interactions |
EXP |
Cyclophosphamide results in increased phosphorylation of and results in increased expression of NTRK2 protein |
CTD |
PMID:12412144 |
|
NCBI chr17:5,934,651...6,245,778
Ensembl chr17:5,933,729...6,244,676
|
|
G |
Nupl2 |
nucleoporin like 2 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of NUPL2 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 4:7,512,326...7,529,106
Ensembl chr 4:7,512,326...7,529,106
|
|
G |
Ocln |
occludin |
decreases expression multiple interactions |
ISO |
Cyclophosphamide results in decreased expression of OCLN protein Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of OCLN protein] |
CTD |
PMID:32151603 |
|
NCBI chr 2:30,527,327...30,577,218
Ensembl chr 2:30,527,715...30,577,218
|
|
G |
Odc1 |
ornithine decarboxylase 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of ODC1 mRNA |
CTD |
PMID:11599041 |
|
NCBI chr 6:42,852,529...42,859,142
Ensembl chr 6:42,852,683...42,859,927
|
|
G |
Ogg1 |
8-oxoguanine DNA glycosylase |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of OGG1 protein |
CTD |
PMID:27032448 |
|
NCBI chr 4:145,282,828...145,289,367
Ensembl chr 4:145,282,797...145,289,326
|
|
G |
Opn3 |
opsin 3 |
affects response to substance |
ISO |
OPN3 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr13:93,716,481...93,746,994
Ensembl chr13:93,716,481...93,746,994
|
|
G |
Osm |
oncostatin M |
affects expression |
ISO |
Cyclophosphamide affects the expression of OSM mRNA |
CTD |
PMID:12624490 |
|
NCBI chr14:84,457,487...84,469,426
Ensembl chr14:84,465,515...84,470,409
|
|
G |
P2rx3 |
purinergic receptor P2X 3 |
increases expression multiple interactions |
EXP |
Cyclophosphamide results in increased expression of P2RX3 protein GR 82334 inhibits the reaction [Cyclophosphamide results in increased expression of P2RX3 protein]; Suramin inhibits the reaction [Cyclophosphamide results in increased expression of P2RX3 protein] |
CTD |
PMID:23666265 |
|
NCBI chr 3:72,403,992...72,447,801
Ensembl chr 3:72,403,993...72,447,801
|
|
G |
P2ry2 |
purinergic receptor P2Y2 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of P2RY2 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 1:166,031,228...166,045,423
Ensembl chr 1:166,031,272...166,037,424
|
|
G |
Paip1 |
poly(A) binding protein interacting protein 1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of PAIP1 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 2:52,300,921...52,328,212
Ensembl chr 2:52,301,798...52,328,205
|
|
G |
Pard3 |
par-3 family cell polarity regulator |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of PARD3 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr19:60,017,746...60,580,628
Ensembl chr19:60,017,746...60,580,651
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases expression increases cleavage decreases expression |
ISO EXP |
[Cladribine co-treated with Cyclophosphamide co-treated with Mitoxantrone] results in decreased expression of PARP1 protein; [Cladribine co-treated with Cyclophosphamide] results in decreased expression of PARP1 protein Cyclophosphamide results in increased expression of PARP1 mRNA Cyclophosphamide results in increased cleavage of PARP1 protein Cy |